<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>In vitro fertilization: Procedure</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">In vitro fertilization: Procedure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">In vitro fertilization: Procedure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacqueline Ho, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3419886426"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In vitro fertilization (IVF) refers to a procedure designed to overcome infertility and produce a live birth as a direct result of the intervention. It is one type of assisted reproductive technology and is now used for indications beyond infertility. In general, IVF involves stimulating the ovaries with a combination of fertility medications, retrieving oocyte(s) from ovarian follicles, and fertilizing these oocytes in the laboratory ("in vitro"). The resultant embryo(s) are transferred into the uterine cavity. These steps typically occur over approximately a two-week interval of time, which is called an IVF cycle.</p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H1174765167"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) have released terminology guidelines in attempt to standardize language for patients, clinicians, and researchers [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'Terminology'</a>.)</p><p class="headingAnchor" id="H3998897029"><span class="h1">INITIAL EVALUATION AND TREATMENT</span></p><p class="headingAnchor" id="H3284829262"><span class="h2">Infertility evaluation</span><span class="headingEndMark"> — </span>Prior to IVF, patients undergo a complete evaluation to identify potential contributors to infertility or issues that may limit IVF success (eg, for patients using IVF for family building unrelated to infertility).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5445.html" rel="external">"Female infertility: Evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7453.html" rel="external">"Approach to the male with infertility"</a>.)</p><p></p><p class="headingAnchor" id="H3650991686"><span class="h2">Assessment of ovarian reserve</span><span class="headingEndMark"> — </span>A variety of tests are available for measurement of ovarian reserve; no single test has demonstrated superiority over the others [<a href="#rid3">3</a>]. We perform cycle day 3 serum follicle-stimulating hormone (FSH) and estradiol levels because they are simple to obtain and cost effective [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/5445.html" rel="external">"Female infertility: Evaluation", section on 'Assessment of ovarian reserve'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – FSH is checked and used to prognosticate response to stimulation but not exclude patients from undergoing IVF. We measure serum FSH and estradiol on cycle day 3 (third day of menstrual bleeding) as the values can help predict patient response to ovarian stimulation. While we do not start IVF cycles in those with serum FSH concentrations &gt;20 milli-international units/mL or serum estradiol concentrations &gt;100 pg/mL (367 pmol/L) because these levels are associated with a poor prognosis, other practices may differ [<a href="#rid5">5-8</a>]. Since FSH concentrations fluctuate from cycle to cycle, individuals with mild to moderate elevations undergo repeat testing [<a href="#rid9">9</a>]. Very high levels (two or more times the upper range of normal for a given assay) have high-negative predictive value for pregnancy and other forms of therapy, including oocyte donation, should be discussed. For individuals with decreased ovarian reserve, there appears to be no age-related decline in fertility when donor oocytes are used [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AMH</strong> – AMH alone is a good predictor of poor or excessive ovarian response but not of live birth [<a href="#rid11">11-14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasound </strong>– For the ultrasound-based tests, a systematic review concluded that an abnormally low antral follicle count (AFC) was a better predictor of poor IVF response than ovarian volume, but neither ultrasound-based test was highly predictive of a low chance of pregnancy [<a href="#rid15">15</a>]. Several studies comparing AMH and ultrasound assessment of AFC reported that AMH more strongly correlated with oocyte yield after controlled ovarian stimulation than AFC [<a href="#rid14">14,16-18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional tests</strong> – Other centers may use the following tests to identify individuals likely to have a poor response to IVF: <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> challenge test (CCCT), ultrasound assessment of antral follicle count (AFC) or ovarian volume, exogenous FSH ovarian reserve test (EFORT), or measurement of inhibin B levels [<a href="#rid4">4,15,19-27</a>]. While virtually all ART programs perform some type of ovarian reserve testing, the value of performing any of these tests has been questioned given their limitations [<a href="#rid3">3,28</a>]. </p><p></p><p class="headingAnchor" id="H1711541897"><span class="h2">Semen analysis</span><span class="headingEndMark"> — </span>A semen analysis is a key component of evaluating male patients prior to fertility therapy, including IVF. (See  <a class="medical medical_review" href="/z/d/html/7453.html" rel="external">"Approach to the male with infertility"</a>.)</p><p class="headingAnchor" id="H1741370496"><span class="h2">Consider alternate therapies if appropriate</span><span class="headingEndMark"> — </span>Most individuals pursue less invasive treatment options prior to IVF. Exceptions include individuals whose source of infertility is only resolved with IVF (eg, blocked fallopian tubes, severe male factor) and females over 40 years of age. The evaluation and management of older female patients is presented separately. (See  <a class="medical medical_review" href="/z/d/html/111561.html" rel="external">"Evaluation and management of infertility in females of advancing age"</a>.)</p><p>Therapies may include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeted treatment for likely cause of infertility</strong> – Initial treatments are aimed at specific causes identified during the infertility evaluation, including ovulatory disorders and uterine factors (eg, intrauterine adhesions). (See  <a class="medical medical_review" href="/z/d/html/5448.html" rel="external">"Female infertility: Treatments"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observation with unprotected intercourse</strong> – For younger individuals with no identified block to conception, we typically advise one year of unprotected intercourse as approximately 85 percent will conceive during that time [<a href="#rid29">29</a>]. A shorter time period (six months of unprotected intercourse) is generally used for individuals aged 35 years or older. (See  <a class="medical medical_review" href="/z/d/html/111561.html" rel="external">"Evaluation and management of infertility in females of advancing age"</a>.)</p><p></p><p class="bulletIndent1">The rationale for a period of correctly timed intercourse is that individuals with open fallopian tubes and without severe male factor infertility have substantial treatment-independent pregnancy rates even if some indications for IVF are present (eg, pelvic disease, endometriosis, and/or unexplained fertility). (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'What are the pregnancy and live birth rates?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovulation induction with IUI </strong>– After an appropriate period of attempted conception with correctly timed intercourse, individuals who have not conceived may be offered three to six cycles of medication-induced ovulation (ie, superovulation) and intrauterine insemination (IUI) before proceeding with IVF.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7407.html" rel="external">"Overview of ovulation induction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7413.html" rel="external">"Procedure for intrauterine insemination (IUI) using processed sperm"</a>.)</p><p></p><p class="headingAnchor" id="H3302640079"><span class="h1">IVF CYCLE</span><span class="headingEndMark"> — </span>The general components of an IVF cycle are pharmacologic ovarian stimulation (ie, ovulation induction or superovulation) and oocyte aspiration. Depending on the goals of the patient, the oocytes may then be fertilized or cryopreserved.</p><p class="headingAnchor" id="H3238721743"><span class="h2">Preparation</span><span class="headingEndMark"> — </span>Prior to an IVF cycle, patients participate in the informed consent process to understand the procedure risks and alternatives. Most patients do not require prophylactic antibiotics, thromboprophylaxis, or steroid therapy but individual care plans may vary based on medical history and risk factors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Informed consent</strong> – The usual surgical risks of bleeding and infection are also included. A general discussion of the informed consent process is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15076.html" rel="external">"Informed procedural consent"</a>.)</p><p></p><p class="bulletIndent1">Specific risks of controlled hyperstimulation and IVF are discussed with all patients and include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical risks &lt;1 percent (bleeding, infection, damage to nearby structures) [<a href="#rid30">30</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other (ovarian torsion &lt;1 percent [<a href="#rid31">31</a>], ovarian hyperstimulation syndrome [OHSS] 1 to 5 percent of cycles [<a href="#rid32">32-34</a>] ) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/3305.html" rel="external">"Ovarian and fallopian tube torsion"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Risks associated with pregnancy after IVF, including a higher risk of preeclampsia, preterm birth, low birth weight, and congenital anomalies, which are magnified in the setting of multiple gestation </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/6788.html" rel="external">"Assisted reproductive technology: Pregnancy and maternal outcomes"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/133130.html" rel="external">"Assisted reproductive technology: Infant and child outcomes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For select patients</strong> – Most patients undergoing IVF do not require thromboprophylaxis or glucocorticoids. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic prophylaxis</strong> – While routine use of antibiotics prior to embryo retrieval is not advised, antibiotic prophylaxis is planned for patients with higher risk of infection, including those with endometriosis, a history of multiple pelvic surgeries, ruptured appendicitis, and pelvic inflammatory disease [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thromboprophylaxis </strong>– Given the relatively young ages and good health of individuals undergoing IVF, most do not require pharmacologic or mechanical thromboprophylaxis prior to an IVF cycle [<a href="#rid37">37,38</a>]. Individuals who may benefit from pharmacologic prophylaxis include those with known thrombophilia or history of venous thromboembolism. Treatment decisions for these patients are made on an individual basis.</p><p></p><p class="bulletIndent2">Calculation of the Caprini score  (<a class="graphic graphic_table graphicRef83739" href="/z/d/graphic/83739.html" rel="external">table 1</a>) to assess individual risk of thromboembolism and selection of prophylaxis is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use of glucocorticoids</strong> – Glucocorticoids are often used prior to IVF but use is not routine nor standardized across IVF programs and the benefit remains unclear. A meta-analysis of two trials comparing the impact of glucocorticoid supplementation or placebo reported similar live birth rates between the groups (odds ratio 1.37, 95% CI 0.69-2.21) [<a href="#rid39">39</a>]. More data is needed to determine whether glucocorticoid supplementation increases the live birth rate.</p><p></p><p class="headingAnchor" id="H3799856504"><span class="h2">Ovarian stimulation</span><span class="headingEndMark"> — </span>Ovarian stimulation refers to "pharmacologic treatment with the intent of inducing development of multiple ovarian follicles" [<a href="#rid40">40</a>]. Previously used terminology included "superovulation," "ovarian hyperstimulation," and "controlled ovarian stimulation." Ovarian stimulation differs from ovulation induction that is used for anovulatory individuals.</p><p class="headingAnchor" id="H3110377743"><span class="h3">Rationale, candidates, and impact on pregnancy rate</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – Ovarian stimulation involves giving the patient drugs to increase the number of mature oocytes available for fertilization with the ultimate goal of increasing live birth rate [<a href="#rid41">41,42</a>]. Use of these protocols also increased the rate of multiple gestations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates</strong> – Ovarian stimulation is for individuals planning an IVF cycle using fresh (ie, not frozen-thawed) embryos. Patients who are using donor eggs or frozen-thawed embryos do not need this step and proceed to preparation for embryo transfer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on pregnancy rate and endometrial receptivity</strong> – Although controlled ovarian stimulation increases the number of oocytes obtained, it also appears to inhibit endometrial receptivity to some degree [<a href="#rid43">43</a>]. The resultant pregnancy rates are at least 10 percent lower compared with cycles without controlled ovarian hyperstimulation [<a href="#rid44">44-47</a>]. The most likely reason for diminished endometrial receptivity is the premature increase in <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> that occurs with all forms of ovarian stimulation [<a href="#rid48">48</a>] and leads to an earlier appearance of the window of implantation and a relative degree of embryo-endometrial dyssynchrony [<a href="#rid49">49</a>]. The magnitude of the effect on endometrial receptivity is not clear, and embryo quality also likely plays a role. Controlled ovarian stimulation not only diminishes endometrial receptivity, but also may interfere with placental development and, in turn, pregnancy outcome [<a href="#rid50">50-53</a>]. (See  <a class="medical medical_review" href="/z/d/html/6788.html" rel="external">"Assisted reproductive technology: Pregnancy and maternal outcomes"</a>.)</p><p></p><p class="headingAnchor" id="H677929124"><span class="h3">Anticipated ovarian response</span><span class="headingEndMark"> — </span>Approximately 10 percent of cycles are discontinued before egg retrieval [<a href="#rid54">54</a>]; the rate increases with increasing age. A cycle may be cancelled if there is poor or excessive ovarian response. Approximately 84 percent of discontinued cycles are due to no or inadequate egg production and 4 percent are due to hyperresponsiveness.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor response </strong>– A poor response describes individuals whose ovaries require large doses of medication for stimulation but produce less than an optimal number of oocytes and/or achieve relatively low estradiol levels. The diagnosis has been applied to (1) individuals who have had a poor ovarian response after going through an IVF cycle, as well as (2) individuals who are likely to have a poor response based on their older age and a pre-cycle abnormal test of ovarian reserve (also called "expected poor responder" [<a href="#rid55">55</a>]). However, there is wide variation in the specific criteria used clinically and in research studies to define poor response [<a href="#rid55">55,56</a>]. In systematic reviews of randomized trials, no interventions have been highly effective for improving poor ovarian response in such patients [<a href="#rid57">57-60</a>]. The important consideration in these patients is whether or not to proceed with IVF using a modified approach, such as a mild stimulation protocol [<a href="#rid61">61,62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High or excessive response </strong>–<strong> </strong>Individuals with a high response to ovarian stimulation produce large numbers of mature oocytes and/or high estradiol levels. Modification of the stimulation protocol is important to avoid ovarian hyperstimulation syndrome (OHSS). (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'What are the risks of the IVF procedure?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocol selection based on anticipated ovarian response</strong> – The selection of a long or short protocol and the specific agents are influenced by the anticipated ovarian response as determined by risk factors or the outcome of a prior IVF cycle. Long protocols are started in the cycle prior to the planned IVF cycle; short cycles are not. The following text is a brief overview:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Good response</strong> – When a good ovarian response is anticipated, then a long protocol with either gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist is typically selected. Agonist protocols are generally preferred over antagonists because of lower cost. GnRH agonist protocols start with Lupron acetate given alone (started in the luteal phase of the prior cycle) or in combination with an oral contraceptive pill (OCP). For an OCP protocol, OCPs are started on day 2 to 3 of the cycle and gonadotropins are started typically on the fourth day after discontinuing OCPs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Poor response </strong>– Short protocols are typically used when a poor ovarian response is anticipated. Stimulation is achieved with <a class="drug drug_general" data-topicid="9607" href="/z/d/drug information/9607.html" rel="external">human menopausal gonadotropins</a> (hMG) or follicle-stimulating hormone (FSH) and spontaneous ovulation is blocked with either a GnRH agonist (by using the initial stimulation of <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> followed by the down regulation) or with a GnRH antagonist. GnRH antagonists are preferred over GnRH agonists for the short protocol.</p><p></p><p class="headingAnchor" id="H2735347983"><span class="h3">Ovarian stimulation protocols</span><span class="headingEndMark"> — </span>The following is an overview of commonly used protocols for controlled ovarian hyperstimulation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of FSH injection</strong> – Whereas multiple regimens of ovarian stimulation may be used, including those that use selective estrogen receptor modulators, such as <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> or <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, most programs utilize regimens that include daily injections of exogenous FSH. This is because these regimens result in higher oocyte yields as well as higher live birth rates per IVF cycle. While a 2015 meta-analysis reported that weekly use of long-acting FSH at doses of 150 to 180 mcg resulted in similar live birth rates compared with daily FSH injections [<a href="#rid63">63</a>], these medications are available for clinical use outside of the United States. Both standard and long-acting FSH preparations cause a reliable increase in serum FSH levels, which then stimulate multifollicular development in the ovaries. Choice of medication is determined by availability and cost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH agonist (long) protocol</strong> – Long protocols have two parts: pituitary suppression followed by ovarian stimulation  (<a class="graphic graphic_figure graphicRef76439" href="/z/d/graphic/76439.html" rel="external">figure 1</a>). Pituitary suppression is begun the cycle prior to the planned ovarian stimulation to prevent luteinizing hormone (LH) surge before the cohort of stimulated ovarian follicles is mature. The long GnRH agonist protocol is typically chosen for those with good ovarian reserve to achieve synchronous follicle growth. It is not as commonly used as a GnRH antagonist protocol because a GnRH agonist trigger is not part of the protocol (use of a GnRH agonist trigger can decrease risk of OHSS).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pituitary suppression</strong> – One commonly used regimen to suppress pituitary LH release begins with a GnRH agonist that is administered daily for approximately two weeks or until down-regulation is complete (hence, "long protocol"). This protocol is used in a good-responder population, including those with favorable ovarian reserve markers. The long GnRH agonist protocol is less commonly used than antagonist protocols due to an inability to use the GnRH agonist trigger (which is used to prevent OHSS). It is still a protocol option for expected good responders in whom OHSS is less likely. </p><p></p><p class="bulletIndent2">In the United States, either OCPs or <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate are given orally for five to seven days prior to initiating the <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> acetate, after which there is an overlap of leuprolide and OCPs/norethindrone acetate for roughly one week. A daily dose of leuprolide acetate 0.5 to 1 mg is given subcutaneously during this time and for the remainder of the stimulation. Typically the leuprolide acetate is given for a minimum of 10 days before stimulation starts, and subsequently throughout the stimulation until the day of the trigger shot (another 10 days on average).</p><p></p><p class="bulletIndent2">European clinicians more commonly use a single depot injection containing higher doses of the drug (typically the daily dosing is performed in the United States) [<a href="#rid64">64</a>]. Alternatively, <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> acetate can be initiated in the luteal phase of the proceeding cycle to avoid stimulating a release of endogenous FSH and LH since those hormones are relatively low in the luteal phase. Down-regulation is verified by serum estradiol measurement less than 30 pg/mL, prior to starting stimulation medications. Serum estradiol is measured on the day of stimulation start (if starting on day 2/3 of menses) or prior to stimulation start while on OCPs before they are discontinued approximately four days before stimulation start.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ovarian stimulation</strong> – For ovarian stimulation, hMG, FSH, or both [<a href="#rid65">65</a>] is administered in a dose of 150 to 450 (maximum dose) international units/day subcutaneously to stimulate follicular growth [<a href="#rid65">65,66</a>]. Individuals with good ovarian response require lower doses of medication.</p><p></p><p class="bulletIndent2">While one meta-analysis of seven trials reported increased live birth rates with use of hMG versus recombinant FSH, the issue of hMG versus FSH alone remains controversial and a definitive advantage of one type of stimulation over the other has not yet been established. The GnRH agonist is continued at a lower dose to prevent a premature surge in LH secretion. The dose of hMG, FSH, or both is subsequently adjusted according to follicular growth (as determined by transvaginal ultrasonography) and serum estradiol concentrations (an indicator of granulosa cell proliferation).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a "step-down" protocol, the starting dose of gonadotropin is high, and this is followed by gradual reductions in dose during the cycle depending on the response.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a "step-up" protocol, the starting dose of gonadotropin is low and is then gradually increased during the cycle depending on the response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH agonist flare (short) protocol</strong> –<strong> </strong>There are several variations of short GnRH agonist protocols  (<a class="graphic graphic_figure graphicRef76439" href="/z/d/graphic/76439.html" rel="external">figure 1</a>).<strong> </strong>The general approach is described here.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Background</strong> – In patients who are poor responders to ovarian stimulation, the GnRH agonist may be administered in conjunction with ovarian stimulation, so that the initial (agonistic) response of the pituitary can be used for ovarian stimulation. These so-called "flare" protocols are initiated at the time of spontaneous menstruation or after several days or weeks of OCPs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regimen</strong> – While several regimens exist, a common one uses a low-dose of <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a>, 40 mcg twice daily, started on day 2 of bleeding or three to five days after the last OCP. This regimen is called a "microdose Lupron flare" and is most often combined with 450 international units of FSH or hMG. If a pure FSH protocol is used, then low-dose hCG can be added when the lead follicle is 14 mm to provide LH activity for follicular maturation. Initially, the release of FSH and LH from endogenous stores caused by leuprolide provides additional stimulation to the growing follicles, and subsequently prevents premature LH surges, as down-regulation is complete by day 5 of stimulation [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH antagonist protocol</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Background</strong> – GnRH antagonists result in more rapid pituitary desensitization than GnRH agonists. The GnRH antagonist protocol can be utilized in conjunction with oral ovulation induction agents such as <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate or <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> in patients with a predicted poor response.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In good-responder protocols, a lower dose of gonadotropins is used. Providers trigger ovulation with a GnRH agonist, which minimizes the risk of OHSS.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In poor-responder protocols, typically the maximum dose of gonadotropins is used in combination with an oral agent like <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate, which harnesses endogenous stores of FSH and LH that help stimulate follicle growth in addition to the exogenous gonadotropins.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regimens</strong> – A GnRH antagonist-based protocol allows for ovarian stimulation to begin either at the onset of menses or in the luteal phase of the menstrual cycle (luteal start) to speed the IVF process for medically indicated indications.</p><p></p><p class="bulletIndent2">An antagonist is administered mid-stimulation in a flexible or fixed protocol.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a flexible protocol, the GnRH antagonist is initiated when the lead follicle is typically around 14 mm in greatest diameter as this is when LH receptors are typically found on follicles, which places the oocyte at risk of premature ovulation.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a fixed protocol, the GnRH antagonist is administered first, starting on a particular cycle day, usually day 6.This approach has been associated with reduced risk of ovarian hyperstimulation syndrome [<a href="#rid68">68</a>]. </p><p></p><p class="bulletIndent2">In both protocols GnRH antagonists, once started, are continued until the night of ovulatory trigger to prevent breakthrough ovulation.</p><p></p><p class="headingAnchor" id="H1791780885"><span class="h2">Triggers for ovulation</span><span class="headingEndMark"> — </span>When the ovarian follicles are judged to be mature (commonly two or more follicles with a mean diameter of 16 to 18 mm, depending on the protocol utilized, and, in some centers, a serum estradiol level of 200 pg/mL [734 pmol/L] per codominant follicle), a trigger is administered to initiate the ovulatory cascade.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Commonly used drugs </strong>– Available agents to trigger ovulation include hCG (recombinant or urinary) and/or GnRH agonists. Selection is based on patient characteristics, risk for OHSS, intent to transfer fresh embryos among others.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>hCG only </strong>– hCG binds the LH receptor to induce the ovulatory cascade and can be used for triggering ovulation in any protocol.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>hCG recommended</strong> – hCG is the only option for triggering ovulation in GnRH agonist protocols. It is recommended over GnRH agonist triggers in patients with hypothalamic amenorrhea (who will not respond to a GnRH agonist), in those at low risk for OHSS, and those considering fresh embryo transfer.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>hCG preferred</strong> – hCG trigger is preferred over GnRH agonist in patients for whom fresh embryo transfer is considered as there is no regression of the corpus luteum (unlike with the GnRh agonist trigger).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Urinary versus recombinant hCG</strong> – Urinary and recombinant hCG preparations result in similar clinical outcomes when used for induction of final follicular maturation [<a href="#rid69">69</a>]. A dose of 250 mcg of recombinant hCG appears to be equivalent to the standard doses of urinary hCG (5000 to 10,000 units) [<a href="#rid68">68</a>]. However, one concern with hCG is its long half-life and association with increasing risk of OHSS. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'What are the risks of the IVF procedure?'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recombinant human LH </strong>–<strong> </strong>Recombinant human LH (15,000 to 30,000 international units), which has a shorter half-life and is available outside of the United States, has been compared with hCG (5,000 international units) as the ovulatory trigger in 259 women undergoing IVF [<a href="#rid70">70</a>]. An LH dose between 15 and 30,000 international units was as effective as hCG for number of oocytes retrieved, embryo number, and clinical pregnancy, and recombinant LH was associated with a significantly lower risk of OHSS than hCG.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>GnRH agonists</strong> <strong>only </strong>–<strong> </strong>GnRH agonist trigger is generally reserved for individuals on GnRH antagonist-based stimulation protocols who are at increased risk of OHSS as it is associated with reduced rates of OHSS; however, it may be associated with lower pregnancy and live birth rates when used with fresh embryo transfer without luteal support [<a href="#rid71">71</a>]. Formulations include injection and nasal spray.</p><p></p><p class="bulletIndent2">Patients that have hypothalamic amenorrhea or dysfunction (ie, those that have been on long-standing OCPs) are at high risk of not responding to the trigger. To determine whether or not someone is an appropriate candidate for GnRH agonist trigger, we assess menstrual history and prior combined oral contraceptive (COC) use and duration. Post-trigger labs, including an LH and <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> the morning after trigger is obtained, and an LH above 15 international units and/or progesterone above 3 are used as cutoffs for assessing adequate response [<a href="#rid72">72,73</a>]. A detectable LH (ideally above 5 international units) and day of trigger LH &gt;0.5 international units are also helpful predictors in assessing appropriate candidates for GnRH agonist trigger. In our practice, we give <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> acetate 4 mg intramuscularly (IM) 35 hours prior to retrieval followed by a second dose 12 hours later.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other options </strong>– A <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a>/gonadotropin regimen has also been used for ovulation induction, but a systematic review found insufficient evidence to recommend its use in routine IVF practice [<a href="#rid74">74</a>]. Nevertheless, protocols utilizing clomiphene and gonadotropins may be useful in minimal stimulation regimens or in poor responders [<a href="#rid75">75,76</a>]. (See  <a class="medical medical_review" href="/z/d/html/7400.html" rel="external">"Ovulation induction with clomiphene citrate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor and high response to ovarian stimulation </strong>– Approximately 10 percent of cycles are discontinued before egg retrieval [<a href="#rid54">54</a>]; the rate increases with increasing age. A cycle may be cancelled if there is poor or excessive ovarian response. Approximately 84 percent of discontinued cycles are due to no or inadequate egg production and 4 percent are due to hyperresponsiveness.</p><p></p><p class="headingAnchor" id="H3254610657"><span class="h2">Oocyte retrieval</span><span class="headingEndMark"> — </span>Oocyte retrieval is typically performed by transvaginal ultrasound-guided follicle aspiration done 34 to 36 hours after giving the ovulatory trigger. In patients with: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Analgesia </strong>– Patients are commonly given intravenous sedation and narcotics for analgesia (United States approach), although conscious sedation or regional anesthesia may also be used [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure </strong>–<strong> </strong>Under ultrasound guidance, a needle is introduced through the vaginal side wall and into the ovary (transvaginal aspiration) or through the abdominal wall (if the ovaries are not easily accessible through the vagina). Each follicle is sequentially aspirated until all visible follicles are collapsed  (<a class="graphic graphic_figure graphicRef82492" href="/z/d/graphic/82492.html" rel="external">figure 2</a>). This procedure can take 5 to 30 minutes depending on the number of follicles to be retrieved. Follicular flushing has been found to be helpful [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks </strong>– There are few complications of transvaginal follicle aspiration. There is a low risk of intraperitoneal bleeding from the ovary or a pelvic blood vessel as well as a small risk of needle injury to the urinary or gastrointestinal tracts. Since the adoption of prophylactic antibiotics, postprocedure infection rates approach 0 percent [<a href="#rid79">79-82</a>].</p><p></p><p class="headingAnchor" id="H1496074851"><span class="h2">Fertilization in vitro</span><span class="headingEndMark"> — </span>To achieve fertilization, recovered oocytes are mixed with spermatozoa in a small volume of culture medium. The optimum number of hours for incubation of sperm and oocytes has not been determined [<a href="#rid83">83</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertilization</strong> – Typical fertilization rates with IVF are around 70 to 80 percent. Among couples with mild male factor infertility, the probability of fertilization may be increased by the use of high concentrations of sperm or preincubation of sperm in special buffer solutions [<a href="#rid84">84</a>]. For patients who use donor sperm, there does not appear to be a difference in live birth rates for donor versus nondonor sperm, per transfer [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertilization failure</strong> –<strong> </strong>The incidence of total fertilization failure after IVF with normal sperm ranges from 4 to 16 percent; for these individuals, the likelihood of recurrent failure in subsequent IVF cycles is approximately 30 percent [<a href="#rid86">86,87</a>]. Patients with past fertilization problems or with severe male factor infertility are offered micromanipulation and intracytoplasmic sperm injection (ICSI) [<a href="#rid88">88</a>]. The resultant fertilization rates are comparable to those in couples without male factor infertility [<a href="#rid89">89</a>]. Fertilization can be performed with freshly ejaculated sperm or sperm obtained from the epididymis or testis [<a href="#rid90">90,91</a>].</p><p></p><p class="headingAnchor" id="H4228086682"><span class="h2">Embryo management</span><span class="headingEndMark"> — </span>Initial embryo management includes confirmation of fertilization and embryo hatching. Embryos are selected for transfer either by morphologic grading or the results of preimplantation genetic testing (PGT; if performed). A detailed discussion of culture media and embryo growth in vitro is beyond the scope of this review, and can be found elsewhere [<a href="#rid92">92,93</a>].</p><p class="headingAnchor" id="H1344360253"><span class="h3">Initial embryo management</span><span class="headingEndMark"> — </span>Briefly, initial embryo management consists of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirm fertilization </strong>– Fertilization of the oocyte is confirmed by observing two pronuclei within the zygote approximately 18 hours after insemination or ICSI. After fertilization, the individual cells of each embryo ("blastomeres") divide every 12 to 14 hours, so that the embryo reaches approximately eight cells by 72 hours after egg retrieval. Embryos between days 2 and 4 are called "cleavage stage embryos." The blastocyst stage is reached by approximately day 5 after retrieval, and implantation is expected by day 7 after egg retrieval, so transfer should take place prior to this time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Embryo hatching </strong>– "Hatching" is a natural process in which an embryo expands and eventually breaks through the zona pellucida in order to implant on the surface of the endometrium (the lining of the uterus). "Assisted hatching" refers to a laboratory procedure whereby the zona pellucida around the day 3 embryo is mechanically or chemically opened to assist the embryo in hatching from the zona approximately three days later (or at the blastocyst stage, for which the embryo will hatch one day later). The procedure may improve the percentage of embryos that implant in selected cases with poor prognosis (eg, ≥2 failed IVF cycles and poor embryo quality and older women [<a href="#rid94">94,95</a>]), but its value remains controversial [<a href="#rid95">95,96</a>].</p><p></p><p class="headingAnchor" id="H2397705012"><span class="h3">Role of preimplantation genetic testing for aneuploidy (PGT-A)</span><span class="headingEndMark"> — </span>PGT-A is commonly used to evaluate embryos for chromosomal aneuploidy, prioritize which embryos to transfer, and increase utilization of single embryo transfer to reduce rates of multiple gestation [<a href="#rid97">97,98</a>]. If PGT-A is planned, embryonic DNA is obtained from the embryo by removing cells from the trophectoderm at the blastocyst stage, when the embryonic cells have differentiated into the inner cell mass and the trophectoderm. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Universal PGT-A</strong> – While the use of PGT-A has been increasing with the goals of improving live birth rate and reducing the rate of pregnancy loss, universal PGT-A to increase live birth rates has not been established and universal PGT-A may actually reduce live birth rate [<a href="#rid99">99-101</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PGT-A</strong> <strong>for advanced reproductive age</strong> – Patients of advanced reproductive age may benefit from PGT-A as this group has a higher proportion of aneuploid embryos. The ongoing pregnancy and live birth rates from a euploid transfer are higher than those from an untested blastocyst and the miscarriage rate is reduced when transferring a euploid embryo [<a href="#rid102">102</a>]. However, counseling regarding the attrition through the IVF process is important as more than one cycle may be required to achieve a euploid embryo. </p><p></p><p>Detailed discussions of PGT and advanced maternal age can be found separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/111561.html" rel="external">"Evaluation and management of infertility in females of advancing age"</a>.)</p><p></p><p class="headingAnchor" id="H368877202"><span class="h3">Embryo selection</span><span class="headingEndMark"> — </span>Embryo(s) with high-implantation potential are selected from an available cohort based on morphological criteria or based on genetic test results (if PGT-A was performed). </p><p>Additional modalities for embryo selection that have been investigated but are of unclear value include:</p><p class="bulletIndent1"><span class="glyph">●</span>Time lapse monitoring<strong> </strong>–<strong> </strong>Time lapse monitoring is a novel technology for performing semiquantitative evaluation of embryo morphology and developmental kinetics over time without removing the embryo from the incubator; however, systematic reviews have not determined whether it adds value to conventional morphology [<a href="#rid103">103-105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Embryo metabolome evaluation<strong> </strong>– Embryo metabolome evaluation is of unclear value in selecting embryos. A meta-analysis of four trials that evaluated the embryonic metabolome (by assessing the culture medium) as a predictor of pregnancy outcomes reported no improvement in live birth or pregnancy rates (OR 1.11, 95% CI 0.83-1.48; I² = 0 percent; four randomized controlled trials [RCTs]; n = 802), or miscarriage (OR 0.96, 95% CI 0.52-1.78; I² = 0 percent; two RCTs; n = 434) [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of embryo culture media<strong> </strong>– PGT performed on spent embryo culture media has been explored as a potential alternative to trophectoderm biopsy for the selection of euploid embryos. However, studies have yet to demonstrate consistent accuracy and it is not routinely used in clinical settings [<a href="#rid107">107-109</a>].</p><p></p><p class="headingAnchor" id="H3496591852"><span class="h2">Embryo transfer</span><span class="headingEndMark"> — </span>After fertilization, embryos are maintained in culture for a variable time period prior to transfer. Guidelines are available regarding IVF laboratories and embryo transfer technique [<a href="#rid110">110-112</a>].</p><p class="headingAnchor" id="H2048098640"><span class="h3">Endometrial preparation for frozen-thawed embryo transfer</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal priming </strong>– Patients undergoing embryo transfer with frozen embryos can either undergo priming with exogenous estrogen and <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> or use a modified or natural cycle regimen. Natural cycle regimens, including home monitoring of ovulation, may be an option for patients with regular ovulatory menstrual cycles [<a href="#rid113">113</a>]. Anovulatory patients have the option of a modified natural FET cycle that includes use of an ovulation induction drug. The regimens used with hormonal priming cycles are identical to those used during egg donation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Natural cycle IVF'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'</a>.)</p><p></p><p class="bulletIndent1">A meta-analysis concluded that no specific protocol for endometrial preparation was superior to any other; all led to similar results in terms of endometrial receptivity and implantation rate [<a href="#rid114">114</a>]. However, the timing of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> administration influenced the outcome: when progesterone was initiated prior to egg retrieval in oocyte donation, the pregnancy rate was lower than when progesterone started on the day of egg retrieval or the day after.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques not advised</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endometrial injury </strong>– Endometrial injury (ie, scratch) is not recommended in individuals undergoing their first IVF cycle but considered for patients with a prior failed IVF cycle. The technique has been proposed to increase the implantation rate, and ultimately, increase the live birth rate, although supporting data are limited. If performed, this procedure is typically done with an endometrial biopsy-type pipelle in the luteal phase prior to the IVF cycle or transfer.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Similar outcomes with and without endometrial scratch – A 2019 meta-analysis evaluated data from 14 trials, including over 2500 participants, on the impact of endometrial scratch on pregnancy rates with IVF. Due to the significant heterogeneity in the trials, they were only able to evaluate the outcome in couples with one failed full IVF/ICSI cycle. Both groups had similar outcomes for live birth rate (relative risk [RR] 1.01, 95% CI 0.68-1.51), clinical pregnancy rate (RR 1.04, 95% CI 0.74-1.45), pregnancy loss (RR 0.82, 95% CI 0.57-1.17), and multiple pregnancy rate (RR 1.06, 95% CI 0.84-1.35) [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Possibly increased live birth rate with endometrial scratch – A subsequent randomly assigned trial (SCRATCH trial) that included 933 participants reported a possible improvement in live birth rates with use of endometrial scratch prior to IVF (4.6 percent more live births in the scratch versus control group in women with one prior failed IVF/ICSI [RR 1.24, 95% CI 0.96-1.59]) [<a href="#rid116">116</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Testing of endometrial receptivity</strong> – Analysis of endometrial gene expression to identify the receptive phase, and therefore optimal timing for embryo transfer, has been proposed as a technique to increase the live birth rate, particularly for patients with prior unsuccessful transfers or implantations [<a href="#rid117">117-119</a>]. However, a multicenter trial comparing outcomes of euploid blastocyst transfers based on endometrial receptivity testing or using standard timing practices reported similar live birth rates between the groups (live birth rates 58.5 versus 61.9 percent, respectively, rate ratio 0.95, 95% CI 0.79-1.13) [<a href="#rid120">120</a>]. The trial findings add to the body of evidence that routine use of genomic endometrial receptivity testing to time embryo transfer does not improve outcomes [<a href="#rid121">121</a>].</p><p></p><p class="headingAnchor" id="H2313209299"><span class="h3">Embryo stage</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cleavage stage</strong> – Cleavage-stage embryos (two to four days after retrieval) are transferred to the uterus approximately 72 hours after egg retrieval (four to eight cell, cleavage stage) [<a href="#rid54">54</a>]. While a meta-analysis of 12 trials did not find a difference in live birth, miscarriage, or ectopic pregnancy rates between day 2 and day 3 embryo transfers, the additional 24 hours in culture from day 2 to day 3 allowed identification of embryos that stopped dividing and thus were not viable [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blastocyst stage </strong>– Blastocyst-stage embryos (five to seven days after retrieval) are transferred on day 5  (<a class="graphic graphic_figure graphicRef85802" href="/z/d/graphic/85802.html" rel="external">figure 3</a>). Delaying transfer until the blastocyst stage allows selection of higher quality embryos and enables transfer at the time a naturally fertilized in vivo embryo would have reached the uterine cavity. However, the live birth rate per oocyte retrieval may not improve because fewer embryos are available for transfer due to loss of embryos that did not survive in vitro to day 5.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Advantages</strong> –<strong> </strong>Major advantages of blastocyst stage transfer are the ability to perform PGT and the resultant reduction in multiple gestation achieved with single blastocyst transfer [<a href="#rid123">123</a>]. (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Disadvantages</strong> –<strong> </strong>Compared with cleavage stage transfer, blastocyst transfer does not appear to increase the risk of congenital anomalies compared with cleavage-stage transfer or spontaneous conception but may be associated adverse pregnancy outcomes such as preterm birth [<a href="#rid124">124,125</a>]. (See  <a class="medical medical_review" href="/z/d/html/6785.html" rel="external">"Spontaneous preterm birth: Pathogenesis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impact on sex ratio and multiple gestation</strong> –<strong> </strong>With blastocyst culture, there is a higher male-to-female sex ratio, and there is an association with male sex and preterm birth, which may be the driver of the increased preterm birth rate with this approach [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Additionally, with blastocyst transfers there is a small increased risk of monozygotic twinning (blastocyst stage 2.8 versus cleavage stage 2.09 percent) [<a href="#rid127">127</a>]. However, these risks are offset by the increased utilization of single embryo transfer with blastocysts (particularly euploid blastocysts after PGT for aneuploidies [PGT-A]), which results in a higher rate of singleton birth and a decrease in multifetal gestation as opposed to transfers with multiple cleavage stage embryos. (See  <a class="medical medical_review" href="/z/d/html/7417.html" rel="external">"Strategies to control the rate of high order multiple gestation"</a>.) </p><p></p><p class="headingAnchor" id="H3774333809"><span class="h3">Transfer</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure</strong> –<strong> </strong>Embryos are inserted into the uterus using a catheter via the cervix [<a href="#rid128">128</a>]. Embryo transfer is performed in a procedure room where anesthesia is offered. The transcervical route is the easiest and the least traumatic to the patient. All embryos that are to be transferred are loaded into the transfer catheter at one time in a volume of approximately 20 microliters. Under ultrasound guidance, they are placed 1 to 2 cm from the top of the uterine cavity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Number of embryos transferred</strong> –<strong> </strong>The number of embryos transferred is influenced by maternal age, the number of oocytes retrieved, and availability of embryos for cryopreservation as well as by regional laws and guidelines  (<a class="graphic graphic_table graphicRef59373" href="/z/d/graphic/59373.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef112844" href="/z/d/graphic/112844.html" rel="external">table 3</a>) [<a href="#rid129">129</a>]. In general, one to two embryos are transferred [<a href="#rid129">129</a>]. Cycles that result in a high number of oocytes and yield a large number of embryos for cryopreservation are associated with higher pregnancy rates [<a href="#rid130">130,131</a>]. Transferring more than one embryo increases the chance for a pregnancy, but also increases the chance of multiple gestation  (<a class="graphic graphic_table graphicRef59373" href="/z/d/graphic/59373.html" rel="external">table 2</a>) [<a href="#rid129">129,132</a>]. (See  <a class="medical medical_review" href="/z/d/html/7417.html" rel="external">"Strategies to control the rate of high order multiple gestation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of technique variations</strong> – Touching the catheter to the top of the cavity or otherwise inducing uterine cramping by a traumatic transfer technique is thought to decrease the success of the procedure. Despite initial conflicting opinions and data, endometrial scratching prior to embryo transfer does not significantly increase the live birth rate [<a href="#rid133">133-135</a>]. However, the type of catheter (soft versus hard) and other aspects of the transfer technique, such as use of ultrasound guidance, can affect the success of transfer [<a href="#rid136">136-140</a>]. Operator experience remains a major factor in the success of the procedure, and details of the technique must be adapted to each patient on an individual basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-transfer</strong> – After transfer, the catheter is checked to ensure there are no retained embryos. Although there is a theoretic possibility of losing embryos out of the cervix or into the fallopian tubes after embryo transfer, available evidence does not support use of a fibrin sealant or other types of "embryo glue" post-embryo transfer improve clinical pregnancy rates [<a href="#rid141">141</a>].</p><p></p><p class="headingAnchor" id="H1896701943"><span class="h3">Luteal phase support</span><span class="headingEndMark"> — </span>To optimize endometrial receptivity, a <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplement is commonly initiated on the day of or one day after oocyte retrieval or at the time of embryo transfer (ie, the luteal phase) [<a href="#rid43">43,114,142-145</a>]. The optimum route and duration of supplementation has not been established; treatment duration has ranged from obtaining a positive or negative pregnancy test to the end of the first trimester [<a href="#rid146">146-150</a>].</p><p>In the absence of data indicating superiority of one treatment, we do the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fresh embryo transfer</strong> –<strong> </strong>Continue <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> support until 10 weeks gestation with micronized progesterone 200 mg in the vagina twice daily. Other experts may use intravaginal progestin inserts (100 mg twice daily) or gel (90 mg once or twice daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frozen embryo transfer</strong> –<strong> </strong>Continue estrogen and <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> support until the end of the first trimester. We use IM progesterone 50 mg daily in combination with vaginal progesterone 200 mg BID for frozen embryo transfers. One trial evaluating vitrified embryo transfer cycles reported that luteal phase support with IM progesterone led to higher live birth rates as compared with vaginal progesterone used alone [<a href="#rid151">151</a>]. </p><p></p><p>While intramuscular <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> (progesterone in oil) and vaginal progesterone preparations (suppositories, tablets, gel, or ring) are similarly effective [<a href="#rid152">152-155</a>], oral progesterone appears to be less effective [<a href="#rid156">156</a>]. Although intramuscular progesterone is more painful for the patient, it is commonly used because it is associated with less luteal phase bleeding than vaginal progesterone. Regardless of route of administration, these progesterone preparations and doses are not associated with congenital anomalies or virilization [<a href="#rid143">143</a>].</p><p>While hCG can be used with <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> or alone for luteal phase support, it is not more effective than progesterone alone and increases the risk of OHSS [<a href="#rid157">157</a>]. Meta-analyses show that estrogen supplementation does not enhance pregnancy rates [<a href="#rid158">158,159</a>]. However, estradiol is commonly administered along with vaginal progesterone to prevent late luteal vaginal bleeding.</p><p class="headingAnchor" id="H2569132694"><span class="h2">Cryopreservation</span><span class="headingEndMark"> — </span>Excess embryos (ie, beyond those that can be safely transferred) can be cryopreserved for future use. Having excess embryos available for cryopreservation is a surrogate marker of embryo quality [<a href="#rid160">160</a>]. (See  <a class="medical medical_review" href="/z/d/html/121395.html" rel="external">"Fertility preservation: Cryopreservation options", section on 'Embryo'</a>.)</p><p class="headingAnchor" id="H1185792406"><span class="h3">Outcomes of frozen-thawed embryos</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Embryo survival</strong> –<strong> </strong>While both slow freezing and vitrification (ultrarapid freezing) are safe and effective methods of cryopreservation, vitrification is preferred because of survival rates above 90 percent [<a href="#rid161">161,162</a>]. In the past, approximately 20 percent of embryos did not survive the freezing/thawing process, which is thought to be due to subtle damage suffered by the embryo during the cooling and/or warming transition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perinatal outcomes</strong> –<strong> </strong>Systematic reviews of observational studies have reported that children born after transfer of cryopreserved embryos have different perinatal outcomes than those born after transfer of fresh embryos [<a href="#rid46">46,161,163-165</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower rates of preterm birth, low birth weight, growth restriction, perinatal mortality</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comparable rates of congenital malformation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased rates of preeclampsia and placenta accreta spectrum</p><p></p><p class="bulletIndent1">The reason for some better perinatal outcomes of children born after cryopreservation as compared with children born after fresh transfer in most studies is not known but may be related to differences in endometrial receptivity between women undergoing fresh versus cryopreserved embryo transfer (eg, adverse effects of ovarian stimulation in fresh cycles, asynchrony). The lower serum E2 levels associated with frozen-thawed embryo and donor egg transfer cycles may result in better placentation. It is also possible that embryos that survive freezing and thawing are of better quality than fresh embryos. (See  <a class="medical medical_review" href="/z/d/html/133130.html" rel="external">"Assisted reproductive technology: Infant and child outcomes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric outcomes </strong>–<strong> </strong>Outcome data on growth, childhood morbidity, and mental development are limited, but few differences have been reported between children born from cryopreserved embryos compared with fresh embryos.</p><p></p><p class="headingAnchor" id="H779218064"><span class="h3">Freeze-all cycles</span><span class="headingEndMark"> — </span>Based on improved obstetric outcomes with frozen-thawed embryos, some experts have proposed freeze-all cycles, in which all embryos are frozen for future use in a cycle that is not linked to ovarian hyperstimulation. The live birth rates from cycles using frozen-thawed embryos appear to be similar to cycles using fresh embryo cycles [<a href="#rid166">166-170</a>], and systematic reviews suggest improved obstetric outcomes [<a href="#rid46">46,161,163,164</a>]. Other potential benefits of freeze-all cycles include lower rates of OHSS for patients with polycystic ovarian syndrome undergoing IVF and lower incidence of ectopic pregnancy [<a href="#rid167">167,171-174</a>]. However, factors that may negatively impact live birth rates following a freeze-all strategy include embryo stage at transfer (cleavage stage embryos compared with blastocysts) and increasing duration of storage (up to two years) [<a href="#rid175">175-177</a>].</p><p>The rates of ovarian hyperstimulation are lower for frozen cycles [<a href="#rid168">168</a>]. (See  <a class="medical medical_review" href="/z/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H1396007911"><span class="h3">Storage duration and future use</span><span class="headingEndMark"> — </span>There is no scientific basis for a maximum duration of storage [<a href="#rid178">178</a>]. Options for cryopreserved embryos include transfer at a future date, donation to other subfertile couples or for research, or disposal [<a href="#rid179">179-181</a>].</p><p class="headingAnchor" id="H1867707635"><span class="h2">IVF variations</span></p><p class="headingAnchor" id="H2035142331"><span class="h3">Natural cycle IVF</span><span class="headingEndMark"> — </span>Natural cycle (unstimulated) IVF refers to IVF without the use of exogenous gonadotropins to induce growth of multiple follicles. The natural cycle is commonly augmented with a mid-cycle dose of hCG to stimulate ovulation [<a href="#rid182">182,183</a>]. In a few centers, however, timing of oocyte retrieval is based on the occurrence of a spontaneous LH surge [<a href="#rid184">184</a>]. Natural cycle IVF accounts for &lt;1 percent of IVF cycles in the United States, but is more popular elsewhere [<a href="#rid185">185</a>]. Candidates are generally females ≤35 years of age or those &gt;36 years with normal ovarian response [<a href="#rid186">186</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential benefits</strong> – Compared with conventional IVF, unstimulated IVF or cycles that utilize "gentle" stimulation protocols are associated with decreased risk of OHSS and multiple gestation, lower cost, and potentially less stress. Cost is lower because fewer drugs are used and there is no need for embryo storage. Additionally, natural cycle IVF has been associated with lower rates of preterm birth and low birth weight, although the absolute difference in risk is likely small [<a href="#rid187">187</a>]. At least one study has reported that the experience of unstimulated IVF was less stressful for patients than IVF with gonadotropin stimulation [<a href="#rid188">188</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower live birth rate</strong> –<strong> </strong>Compared with conventional IVF, natural cycle IVF has a higher implantation rate per oocyte collected but lower success rates, in part because fewer oocytes are obtained per cycle [<a href="#rid189">189</a>]. In a meta-analysis of six trials comparing natural cycle or modified natural cycle IVF versus standard IVF, the authors concluded a female with a 53 percent chance of live birth using standard IVF would have a 34 to 53 percent chance of success with natural cycle IVF [<a href="#rid190">190</a>]. The findings were imprecise for these and other outcomes (eg, multiple gestation rate).</p><p></p><p class="headingAnchor" id="H1271196231"><span class="h3">In vitro maturation</span><span class="headingEndMark"> — </span>In vitro maturation of immature oocytes from unstimulated cycles is an emerging technology. Major advantages are the avoidance of large doses of gonadotropins and their associated high costs, risk of OHSS, and potential adverse effects on hormone-sensitive tissues (eg, breast cancer) [<a href="#rid191">191</a>]. Development of the technique and assessment of its role in fertility treatment, as well as assessment of children conceived with this technology, is ongoing.</p><p>A variation of the above technique involves in vitro maturation of immature oocytes that are retrieved during a typical stimulated IVF cycle (approximately 20 percent of retrieved oocytes are immature) [<a href="#rid192">192</a>]. Fertilization and clinical pregnancy rates may be lower than with oocytes matured in vivo, but data are limited [<a href="#rid192">192-195</a>].</p><p class="headingAnchor" id="H3477630733"><span class="h1">POST-CYCLE CARE</span></p><p class="headingAnchor" id="H3084551088"><span class="h2">Expected course</span><span class="headingEndMark"> — </span>Post-transfer, the patient can resume regular daily activities.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activity and diet</strong> –<strong> </strong>Neither physical activity nor diet has been shown to have an impact upon the success of embryo implantation or conception. Trials have not reported improved implantation rates with post-transfer bedrest [<a href="#rid141">141</a>]. We typically counsel patients to refrain from intercourse or vigorous activity until the first beta-human chorionic gonadotropin (hCG) is drawn.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common symptoms</strong> – Mild cramping and bloating are normal. Since the cervix is swabbed prior to embryo transfer, some women may pass a small amount of clear or bloody fluid from the vagina shortly after the procedure; this is normal and not a sign that the embryos are being expelled. Breast tenderness and engorgement, bloating, and constipation are not uncommon; they are due to the elevated hormone levels associated with ovarian stimulation, and, to a lesser extent, due to the supplemental hormones used for luteal phase support. Cramping during embryo transfer may be caused by touching the inside of the uterus with the transfer catheter. Cramping after the procedure is likely due to varying degrees of ovarian enlargement and the ovarian hyperstimulation syndrome (OHSS).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms requiring additional evaluation</strong> – Patients with moderate or severe pain or heavy vaginal bleeding require evaluation. Potential IVF-specific causes include infection, ovarian torsion, ectopic pregnancy, heterotopic pregnancy, and more severe forms of OHSS, which is the most common cause of such pain. Other causes of abdominal and pelvic pain, such as appendicitis or urinary tract infection, should also be excluded.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3305.html" rel="external">"Ovarian and fallopian tube torsion"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Heterotopic pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/131912.html" rel="external">"Cesarean scar pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/3311.html" rel="external">"Hysterectomy: Abdominal (open) route"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"</a>.)</p><p></p><p class="bulletIndent1">Pelvic pain occurring many weeks after an IVF cycle should be evaluated as in any woman, pregnant or not, with acute pain. (See  <a class="medical medical_review" href="/z/d/html/5473.html" rel="external">"Acute pelvic pain in nonpregnant adult females: Evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/4807.html" rel="external">"Approach to acute abdominal/pelvic pain in pregnant and postpartum patients"</a>.)</p><p></p><p class="headingAnchor" id="H3891818955"><span class="h2">Monitoring for pregnancy</span><span class="headingEndMark"> — </span>Pregnancy is diagnosed by identification of rising serum hCG levels after transfer.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of serum hCG test</strong> –<strong> </strong>Initial serum hCG is usually obtained no earlier than 12 days after egg retrieval, although some programs start testing later. The rationale is that implantation is thought to occur no earlier than seven days after retrieval; hCG levels may be detected one or two days later. However, late implantations do occur. Once a positive hCG is obtained, serial hCG measurements are performed to monitor whether the rise is normal and consistent with a developing intrauterine pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In frozen embryo transfers, the first beta hCG is drawn nine days after blastocyst transfer or 11 days after cleavage stage transfer (when the patient would be four weeks gestational age).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In either fresh or frozen transfers, if the first beta is positive, we repeat the beta hCG 48 hours later, followed by another beta hCG at five weeks gestational age. We repeat the beta hCG level sooner if an abnormal rise is detected and there is suspicion for an abnormal pregnancy (biochemical pregnancy, abnormal intrauterine pregnancy, or ectopic pregnancy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of exogenous hCG</strong> – Exogenous hCG administration prior to oocyte retrieval results in serum hCG levels between 60 and 300 milli-international units/mL. This hCG is generally cleared by two weeks after administration. As initial serum hCG testing is begun no sooner than 12 days after retrieval, it should not interfere with pregnancy testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation of ultrasound</strong> –<strong> </strong>If the hCG test is positive, ultrasound evaluation of the pregnancy generally begins at six weeks of gestational age (four weeks after retrieval), which is when the fetal heartbeat may first be detected. Both embryo viability and intrauterine location are confirmed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral for obstetric care</strong> – Patients are typically referred for obstetric care once both viability and intrauterine location of the pregnancy have been confirmed. Continued contact is worthwhile for the rare case of heterotopic pregnancy that may occur after IVF, and which may not become apparent until later in the first trimester. The major symptom is pelvic pain. (See  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Heterotopic pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative hCG test</strong> –<strong> </strong>A negative hCG level 14 days after egg retrieval is a strong indication of a failed IVF cycle. The patient is instructed to stop luteal phase supplementation, and menstruation commonly occurs after one to three days. Lack of menses or unusual irregular bleeding should be evaluated with hormonal measurements, since ectopic pregnancies may rarely present with very delayed appearance of hCG in the circulation.</p><p></p><p class="bulletIndent1">Occasionally, a very early positive hCG test becomes negative on follow-up testing and before there is evidence of an intrauterine or extrauterine pregnancy on ultrasound. Menses often occur at the expected time. These very early pregnancy losses are termed "chemical pregnancies."</p><p></p><p class="headingAnchor" id="H4042681550"><span class="h2">Obstetric care</span><span class="headingEndMark"> — </span>Individuals who conceive using IVF procedures are not considered to have high-risk pregnancies based on the fertility treatment. Decisions regarding level of obstetric care and provider are made based on the usual obstetric indications such as underlying medical conditions or advancing age. (See  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Care provider'</a>.)</p><p class="headingAnchor" id="H771979946"><span class="h1">REPEAT IVF CYCLES</span><span class="headingEndMark"> — </span>The optimal timing of repeat embryo transfer following either live birth or pregnancy loss is a common clinical question. While short-interval embryo transfer may be desired by the patient, observational data suggest that intervals of at least six months are associated with improved outcomes [<a href="#rid196">196,197</a>]. Definitive conclusions are limited by the retrospective nature of the available studies and inclusion of embryos that were untested for aneuploidy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interval following live birth</strong> – Following live birth, interpregnancy intervals (IPIs) &lt;12 months are associated with increased risks of preterm birth following both fresh and frozen embryo transfers [<a href="#rid197">197,198</a>]. However, the observational nature of the data and small sample sizes across different preterm birth cut-offs limit definitive conclusions regarding the absolute effect. Risk of preterm birth appears to be attenuated for IPIs of 6 to &lt;12 months compared with IPIs of &lt;6 months [<a href="#rid197">197</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interval following pregnancy loss</strong> – An observational study of 2433 patients who underwent a frozen blastocyst transfer after a clinical pregnancy loss reported that, compared with IPIs 6 to 12 months, IPIs of &lt;3 months and 3 to &lt;6 months were associated with lower live birth rates and higher overall pregnancy loss rates. For each group, singleton live births were: IPI &lt;3 months, 37.6 percent; IPI 3 to &lt;6 months, 40.6 percent; IPI 6 to 12 months, 46.3 percent [<a href="#rid196">196</a>]. The impact on both live birth and pregnancy loss rates were greater for IPIs of &lt;3 months compared with IPIs of 3 to &lt;6 months. Study limitations include use of untested embryos, </p><p></p><p class="headingAnchor" id="H493217871"><span class="h1">RESOURCES FOR PATIENTS AND CLINICIANS</span><span class="headingEndMark"> — </span>In the United States, over 450 fertility clinics provide verified data on the outcomes of all ART cycles started in their clinic. Annual summary reports with detailed descriptions of patient characteristics, procedures, and outcomes are available online from registries in the United States and Europe:</p><p class="bulletIndent1"><span class="glyph">●</span>United States Data: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sartcorsonline.com%2FrptCSR_PublicMultYear.aspx%3FClinicPKID%3D0&amp;token=vdCs7dqmABYrTYLl86e3UG97b7mXarW%2FYt3qRspGNO2WT48e2x3u%2Ba2N883wYLm%2B8kVvKv26gZAPsaAhuIu2pNZkiBTs7PqLYxu%2BTfLDy44%3D&amp;TOPIC_ID=134342" target="_blank">Society for Assisted Reproductive Technology</a> (SART) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>European Data: The European Society of Human Reproduction and Embryology (ESHRE) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.eshre.eu%2FPress-Room%2FResources&amp;token=%2B0rEyHQ1T7gRoXXx698zAhBp7pspeoeGrOEB%2BK8eFiVhe8xuiYNJFXlAI0dehA7Yv2B79nN1q4jvsv5beh%2FQxg%3D%3D&amp;TOPIC_ID=134342" target="_blank">Resources</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>US Centers for Disease Control and Prevention (CDC) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fart%2Fivf-success-estimator%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLPEEE5mPDKSAV0P2SRu5cmrRUfl7oSxoHAmqkWi9Vc7O3RrXnWcOIXfvjLrxwkSdag%3D%3D&amp;TOPIC_ID=134342" target="_blank">IVF Success Estimator</a></p><p></p><p class="headingAnchor" id="H874589981"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114191.html" rel="external">"Society guideline links: Female infertility"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115208.html" rel="external">"Society guideline links: Male infertility or hypogonadism"</a>.)</p><p class="headingAnchor" id="H336041804"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/8394.html" rel="external">"Patient education: In vitro fertilization (IVF) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2541614723"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Prior to IVF, both female and male partners undergo a complete infertility evaluation to identify all potential contributors to infertility. Key components include assessment of ovarian reserve and tubal patency for females and semen analysis for males. (See <a class="local">'Initial evaluation and treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IVF cycle</strong> – The general components of an IVF cycle are pharmacologic ovarian stimulation (ie, ovulation induction or superovulation), oocyte aspiration and fertilization, and embryo transfer. (See <a class="local">'IVF cycle'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preprocedure preparation</strong> – Prior to initiating an IVF cycle, patients participate in the formed consent process to understand the procedure risks and alternatives. Most patients do not require prophylactic antibiotics, thromboprophylaxis, or steroid therapy, but individual care plans may vary based on medical history and risk factors. (See <a class="local">'Preparation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ovarian stimulation</strong> – Ovarian stimulation involves giving the patient drugs to increase the number of mature oocytes available for fertilization with the goal of increasing live birth rate. Use of these protocols also increased the rate of multiple gestations. Individuals who are not using fresh embryos (ie, frozen embryo or donor egg cycle) do not need ovarian stimulation and go directly to endometrial preparation instead. (See <a class="local">'Ovarian stimulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Trigger for ovulation</strong> – When the ovarian follicles are judged to be mature (two or more follicles with a mean diameter of 18 mm or more and a serum estradiol level of 200 pg/mL [734 pmol/L] per codominant follicle), a trigger is administered to initiate the ovulatory cascade. Commonly used drugs include human chorionic gonadotropin (hCG; recombinant or urinary), recombinant human luteinizing hormone (LH), or gonadotropin-releasing hormone (GnRH) agonists. Selection is mainly based on patient characteristics and influenced by drug availability. (See <a class="local">'Triggers for ovulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oocyte retrieval </strong>– Oocyte retrieval is typically performed by transvaginal ultrasound-guided follicle aspiration done 34 to 36 hours after hCG administration. Using transvaginal ultrasound guidance, a needle is introduced sequentially into each follicle and the follicular contents are aspirated  (<a class="graphic graphic_figure graphicRef82492" href="/z/d/graphic/82492.html" rel="external">figure 2</a>). (See <a class="local">'Oocyte retrieval'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fertilization </strong>– To achieve fertilization, recovered oocytes are mixed with spermatozoa in a small volume of culture medium. The optimum number of hours for incubation of sperm and oocytes has not been determined. Typical fertilization rates with IVF are approximately 70 to 80 percent. (See <a class="local">'Fertilization in vitro'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Embryo management</strong> – Initial embryo management includes confirmation of fertilization and embryo hatching. Embryos are selected for transfer either by morphologic grading or the results of preimplantation genetic testing (PGT; if performed). (See <a class="local">'Embryo management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Embryo transfer</strong> – After fertilization, embryos are maintained in culture for a variable time period prior to cryopreservation or transfer. Guidelines are available regarding IVF laboratories and embryo transfer technique. (See <a class="local">'Embryo transfer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Embryo cryopreservation</strong> – Excess embryos (ie, beyond those that can be safely transferred) can be cryopreserved for future use. Having excess embryos available for cryopreservation is a surrogate marker of embryo quality. (See <a class="local">'Cryopreservation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IVF cycle variations</strong> – Variations to conventional IVF include natural cycle IVF and in vitro maturation. Natural cycle (unstimulated) IVF refers to IVF without the use of exogenous gonadotropins to induce growth of multiple follicles; the natural cycle is commonly augmented with a mid-cycle dose of hCG to stimulate ovulation. In vitro maturation of immature oocytes from an unstimulated cycle is an emerging technology. (See <a class="local">'IVF variations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-cycle care</strong> – Post-transfer, the patient can resume regular daily activities. Pregnancy monitoring is performed to confirm both viability and intrauterine location of an established pregnancy. (See <a class="local">'Post-cycle care'</a> above.)</p><p></p><p class="headingAnchor" id="H2479410461"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Richard Paulson, MD, MS, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zegers-Hochschild F, Adamson GD, Dyer S, et al. The International Glossary on Infertility and Fertility Care, 2017. Hum Reprod 2017; 32:1786.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="80e1f3f2edc0e1f3f2edaeeff2e7">[email protected]</span>. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 2020; 113:533.</a></li><li><a class="nounderline abstract_t">Maheshwari A, Fowler P, Bhattacharya S. Assessment of ovarian reserve--should we perform tests of ovarian reserve routinely? Hum Reprod 2006; 21:2729.</a></li><li><a class="nounderline abstract_t">Jain T, Soules MR, Collins JA. Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening. Fertil Steril 2004; 82:180.</a></li><li><a class="nounderline abstract_t">Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991; 55:784.</a></li><li><a class="nounderline abstract_t">Martin JS, Nisker JA, Tummon IS, et al. Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels. Fertil Steril 1996; 65:1238.</a></li><li><a class="nounderline abstract_t">Roberts JE, Spandorfer S, Fasouliotis SJ, et al. Taking a basal follicle-stimulating hormone history is essential before initiating in vitro fertilization. Fertil Steril 2005; 83:37.</a></li><li><a class="nounderline abstract_t">Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995; 64:991.</a></li><li><a class="nounderline abstract_t">Bancsi LF, Broekmans FJ, Mol BW, et al. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril 2003; 79:1091.</a></li><li><a class="nounderline abstract_t">Sauer MV, Paulson RJ, Lobo RA. Reversing the natural decline in human fertility. An extended clinical trial of oocyte donation to women of advanced reproductive age. JAMA 1992; 268:1275.</a></li><li><a class="nounderline abstract_t">Iliodromiti S, Kelsey TW, Wu O, et al. The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update 2014; 20:560.</a></li><li><a class="nounderline abstract_t">Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006; 12:685.</a></li><li><a class="nounderline abstract_t">Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19:26.</a></li><li><a class="nounderline abstract_t">Arce JC, La Marca A, Mirner Klein B, et al. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013; 99:1644.</a></li><li><a class="nounderline abstract_t">Hendriks DJ, Kwee J, Mol BW, et al. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 2007; 87:764.</a></li><li><a class="nounderline abstract_t">Anckaert E, Smitz J, Schiettecatte J, et al. The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod 2012; 27:1829.</a></li><li><a class="nounderline abstract_t">Andersen AN, Witjes H, Gordon K, et al. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod 2011; 26:3413.</a></li><li><a class="nounderline abstract_t">Nelson SM, Klein BM, Arce JC. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. Fertil Steril 2015; 103:923.</a></li><li><a class="nounderline abstract_t">Hendriks DJ, Broekmans FJ, Bancsi LF, et al. Repeated clomiphene citrate challenge testing in the prediction of outcome in IVF: a comparison with basal markers for ovarian reserve. Hum Reprod 2005; 20:163.</a></li><li><a class="nounderline abstract_t">Hazout A, Bouchard P, Seifer DB, et al. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 2004; 82:1323.</a></li><li><a class="nounderline abstract_t">Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? BJOG 2004; 111:1248.</a></li><li><a class="nounderline abstract_t">Hendriks DJ, Mol BW, Bancsi LF, et al. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril 2005; 83:291.</a></li><li><a class="nounderline abstract_t">Kwee J, Schats R, McDonnell J, et al. The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyperresponders to in vitro fertilization. Fertil Steril 2006; 85:1714.</a></li><li><a class="nounderline abstract_t">La Marca A, Giulini S, Tirelli A, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007; 22:766.</a></li><li><a class="nounderline abstract_t">Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod 2008; 23:1359.</a></li><li><a class="nounderline abstract_t">Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009; 91:705.</a></li><li><a class="nounderline abstract_t">Reichman DE, Goldschlag D, Rosenwaks Z. Value of antimüllerian hormone as a prognostic indicator of in vitro fertilization outcome. Fertil Steril 2014; 101:1012.</a></li><li><a class="nounderline abstract_t">Mol BW, Verhagen TE, Hendriks DJ, et al. Value of ovarian reserve testing before IVF: a clinical decision analysis. Hum Reprod 2006; 21:1816.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril 2015; 103:e44.</a></li><li><a class="nounderline abstract_t">Levi-Setti PE, Cirillo F, Scolaro V, et al. Appraisal of clinical complications after 23,827 oocyte retrievals in a large assisted reproductive technology program. Fertil Steril 2018; 109:1038.</a></li><li><a class="nounderline abstract_t">Berkkanoglu M, Coetzee K, Bulut H, Ozgur K. Risk of ovarian torsion is reduced in GnRH agonist triggered freeze-all cycles: a retrospective cohort study. J Obstet Gynaecol 2019; 39:212.</a></li><li><a class="nounderline abstract_t">Steward RG, Lan L, Shah AA, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014; 101:967.</a></li><li><a class="nounderline abstract_t">Luke B, Brown MB, Morbeck DE, et al. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertil Steril 2010; 94:1399.</a></li><li><a class="nounderline abstract_t">Jayaprakasan K, Chan Y, Islam R, et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril 2012; 98:657.</a></li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. Obstet Gynecol 2018; 131:e172. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Pereira N, Hutchinson AP, Lekovich JP, et al. Antibiotic Prophylaxis for Gynecologic Procedures prior to and during the Utilization of Assisted Reproductive Technologies: A Systematic Review. J Pathog 2016; 2016:4698314.</a></li><li><a class="nounderline abstract_t">Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Prevention of Venous Thromboembolism in Gynecologic Surgery: ACOG Practice Bulletin, Number 232. Obstet Gynecol 2021; 138:e1.</a></li><li><a class="nounderline abstract_t">Boomsma CM, Kamath MS, Keay SD, Macklon NS. Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database Syst Rev 2022; 6:CD005996.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="6c0d1f1e012c0d1f1e0142031e0b">[email protected]</span>, Practice Committee of the American Society for Reproductive Medicine. Evidence-based treatments for couples with unexplained infertility: a guideline. Fertil Steril 2020; 113:305.</a></li><li><a class="nounderline abstract_t">Ingerslev HJ, Højgaard A, Hindkjaer J, Kesmodel U. A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate. Hum Reprod 2001; 16:696.</a></li><li><a class="nounderline abstract_t">Paulson RJ, Marrs RP. Ovulation stimulation and monitoring for in vitro fertilization. Curr Probl Obstet Gynecol Infert 1986; 10:497.</a></li><li><a class="nounderline abstract_t">Paulson RJ, Sauer MV, Lobo RA. Embryo implantation after human in vitro fertilization: importance of endometrial receptivity. Fertil Steril 1990; 53:870.</a></li><li class="breakAll">2010 Assisted Reproductive Technology National Summary Report. National Center for Chronic Disease Prevention and Health Promotion. Available at: http://www.cdc.gov/art/ART2010/PDFs/ART_2010_National_Summary_Report.pdf (Accessed on February 18, 2022).</li><li><a class="nounderline abstract_t">Yeh JS, Steward RG, Dude AM, et al. Pregnancy rates in donor oocyte cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26,457 fresh cycles from the Society for Assisted Reproductive Technology. Fertil Steril 2014; 102:399.</a></li><li><a class="nounderline abstract_t">Roque M, Lattes K, Serra S, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril 2013; 99:156.</a></li><li><a class="nounderline abstract_t">Roque M, Valle M, Guimarães F, et al. Freeze-all policy: fresh vs. frozen-thawed embryo transfer. Fertil Steril 2015; 103:1190.</a></li><li><a class="nounderline abstract_t">Saadat P, Boostanfar R, Slater CC, et al. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists. Fertil Steril 2004; 82:167.</a></li><li><a class="nounderline abstract_t">Kolb BA, Najmabadi S, Paulson RJ. Ultrastructural characteristics of the luteal phase endometrium in patients undergoing controlled ovarian hyperstimulation. Fertil Steril 1997; 67:625.</a></li><li><a class="nounderline abstract_t">Shapiro BS, Daneshmand ST, Garner FC, et al. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders. Fertil Steril 2011; 96:344.</a></li><li><a class="nounderline abstract_t">Haouzi D, Assou S, Mahmoud K, et al. Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients. Hum Reprod 2009; 24:1436.</a></li><li><a class="nounderline abstract_t">Richter KS, Shipley SK, McVearry I, et al. Cryopreserved embryo transfers suggest that endometrial receptivity may contribute to reduced success rates of later developing embryos. Fertil Steril 2006; 86:862.</a></li><li><a class="nounderline abstract_t">Shapiro BS, Daneshmand ST, Garner FC, et al. Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of day 5 or day 6 blastocysts may reflect differences in embryo-endometrium synchrony. Fertil Steril 2008; 89:20.</a></li><li class="breakAll">Assisted reproductive technology reports and resources. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/art/ARTReports.htm (Accessed on August 24, 2015).</li><li><a class="nounderline abstract_t">Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011; 26:1616.</a></li><li><a class="nounderline abstract_t">Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? Fertil Steril 2011; 96:1058.</a></li><li><a class="nounderline abstract_t">Shanbhag S, Aucott L, Bhattacharya S, et al. Interventions for 'poor responders' to controlled ovarian hyperstimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev 2007; :CD004379.</a></li><li><a class="nounderline abstract_t">Kyrou D, Kolibianakis EM, Venetis CA, et al. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009; 91:749.</a></li><li><a class="nounderline abstract_t">Xiao J, Chang S, Chen S. The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2013; 100:1594.</a></li><li><a class="nounderline abstract_t">Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015; :CD009749.</a></li><li><a class="nounderline abstract_t">Arslan M, Bocca S, Mirkin S, et al. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril 2005; 84:555.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="e8a9bbbaa5a8899b9a85c6879a8f">[email protected]</span>. Comparison of pregnancy rates for poor responders using IVF with mild ovarian stimulation versus conventional IVF: a guideline. Fertil Steril 2018; 109:993.</a></li><li><a class="nounderline abstract_t">Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015; :CD009577.</a></li><li><a class="nounderline abstract_t">Albuquerque LE, Tso LO, Saconato H, et al. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev 2013; :CD002808.</a></li><li><a class="nounderline abstract_t">van Wely M, Westergaard LG, Bossuyt PM, van der Veen F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril 2003; 80:1086.</a></li><li><a class="nounderline abstract_t">Coomarasamy A, Afnan M, Cheema D, et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008; 23:310.</a></li><li><a class="nounderline abstract_t">Chung K, Fogle R, Bendikson K, et al. Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development. Fertil Steril 2011; 95:317.</a></li><li><a class="nounderline abstract_t">Ludwig M, Doody KJ, Doody KM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003; 79:1051.</a></li><li><a class="nounderline abstract_t">Youssef MA, Abou-Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2016; 4:CD003719.</a></li><li><a class="nounderline abstract_t">European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001; 86:2607.</a></li><li><a class="nounderline abstract_t">Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014; :CD008046.</a></li><li><a class="nounderline abstract_t">Meyer L, Murphy LA, Gumer A, et al. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles. Fertil Steril 2015; 104:637.</a></li><li><a class="nounderline abstract_t">Popovic-Todorovic B, Santos-Ribeiro S, Drakopoulos P, et al. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation. Hum Reprod 2019; 34:2027.</a></li><li><a class="nounderline abstract_t">Gibreel A, Maheshwari A, Bhattacharya S. Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst Rev 2012; 11:CD008528.</a></li><li><a class="nounderline abstract_t">Saadat P, Slater CC, Jain JK, et al. Treatment-associated serum FSH levels in very poor responders to ovarian stimulation. J Assist Reprod Genet 2003; 20:395.</a></li><li><a class="nounderline abstract_t">Kamath MS, Maheshwari A, Bhattacharya S, et al. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev 2017; 11:CD008528.</a></li><li><a class="nounderline abstract_t">Kwan I, Wang R, Pearce E, Bhattacharya S. Pain relief for women undergoing oocyte retrieval for assisted reproduction. Cochrane Database Syst Rev 2018; 5:CD004829.</a></li><li><a class="nounderline abstract_t">Georgiou EX, Melo P, Brown J, Granne IE. Follicular flushing during oocyte retrieval in assisted reproductive techniques. Cochrane Database Syst Rev 2018; 4:CD004634.</a></li><li><a class="nounderline abstract_t">Evers JL, Larsen JF, Gnany GG, Sieck UV. Complications and problems in transvaginal sector scan-guided follicle aspiration. Fertil Steril 1988; 49:278.</a></li><li><a class="nounderline abstract_t">Howe RS, Wheeler C, Mastroianni L Jr, et al. Pelvic infection after transvaginal ultrasound-guided ovum retrieval. Fertil Steril 1988; 49:726.</a></li><li><a class="nounderline abstract_t">Sauer MV, Paulson RJ. Pelvic abscess complicating transcervical embryo transfer. Am J Obstet Gynecol 1992; 166:148.</a></li><li><a class="nounderline abstract_t">Kroon B, Hart RJ, Wong BM, et al. Antibiotics prior to embryo transfer in ART. Cochrane Database Syst Rev 2012; :CD008995.</a></li><li><a class="nounderline abstract_t">Huang Z, Li J, Wang L, et al. Brief co-incubation of sperm and oocytes for in vitro fertilization techniques. Cochrane Database Syst Rev 2013; :CD009391.</a></li><li><a class="nounderline abstract_t">Paulson RJ, Sauer MV, Francis MM, et al. A prospective controlled evaluation of TEST-yolk buffer in the preparation of sperm for human in vitro fertilization in suspected cases of male infertility. Fertil Steril 1992; 58:551.</a></li><li><a class="nounderline abstract_t">Gerkowicz SA, Crawford SB, Hipp HS, et al. Assisted reproductive technology with donor sperm: national trends and perinatal outcomes. Am J Obstet Gynecol 2018; 218:421.e1.</a></li><li><a class="nounderline abstract_t">Barlow P, Englert Y, Puissant F, et al. Fertilization failure in IVF: why and what next? Hum Reprod 1990; 5:451.</a></li><li><a class="nounderline abstract_t">Molloy D, Harrison K, Breen T, Hennessey J. The predictive value of idiopathic failure to fertilize on the first in vitro fertilization attempt. Fertil Steril 1991; 56:285.</a></li><li><a class="nounderline abstract_t">Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 1992; 340:17.</a></li><li><a class="nounderline abstract_t">Society for Assisted Reproductive Technology, American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry. Fertil Steril 2007; 87:1253.</a></li><li><a class="nounderline abstract_t">Nagy Z, Liu J, Cecile J, et al. Using ejaculated, fresh, and frozen-thawed epididymal and testicular spermatozoa gives rise to comparable results after intracytoplasmic sperm injection. Fertil Steril 1995; 63:808.</a></li><li><a class="nounderline abstract_t">Silber SJ, Van Steirteghem AC, Liu J, et al. High fertilization and pregnancy rate after intracytoplasmic sperm injection with spermatozoa obtained from testicle biopsy. Hum Reprod 1995; 10:148.</a></li><li><a class="nounderline abstract_t">Mahadevan MM. Optimization of culture conditions for human in vitro fertilization and embryo transfer. Semin Reprod Endocrinol 1998; 16:197.</a></li><li><a class="nounderline abstract_t">Boiso I, Veiga A, Edwards RG. Fundamentals of human embryonic growth in vitro and the selection of high-quality embryos for transfer. Reprod Biomed Online 2002; 5:328.</a></li><li><a class="nounderline abstract_t">Mansour RT, Rhodes CA, Aboulghar MA, et al. Transfer of zona-free embryos improves outcome in poor prognosis patients: a prospective randomized controlled study. Hum Reprod 2000; 15:1061.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine, Practice Committee of the Society for Assisted Reproductive Technology. Role of assisted hatching in in vitro fertilization: a guideline. Fertil Steril 2014; 102:348.</a></li><li><a class="nounderline abstract_t">Kissin DM, Kawwass JF, Monsour M, et al. Assisted hatching: trends and pregnancy outcomes, United States, 2000-2010. Fertil Steril 2014; 102:795.</a></li><li><a class="nounderline abstract_t">Dahdouh EM. Preimplantation Genetic Testing for Aneuploidy: A Review of the Evidence. Obstet Gynecol 2021; 137:528.</a></li><li><a class="nounderline abstract_t">Forman EJ, Hong KH, Franasiak JM, Scott RT Jr. Obstetrical and neonatal outcomes from the BEST Trial: single embryo transfer with aneuploidy screening improves outcomes after in vitro fertilization without compromising delivery rates. Am J Obstet Gynecol 2014; 210:157.e1.</a></li><li><a class="nounderline abstract_t">Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: <span class="__cf_email__" data-cfemail="fabba9a8b7ba9b898897d495889d">[email protected]</span>, Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion. Fertil Steril 2018; 109:429.</a></li><li><a class="nounderline abstract_t">Yan J, Qin Y, Zhao H, et al. Live Birth with or without Preimplantation Genetic Testing for Aneuploidy. N Engl J Med 2021; 385:2047.</a></li><li><a class="nounderline abstract_t">Paulson RJ. Hidden in plain sight: the overstated benefits and underestimated losses of potential implantations associated with advertised PGT-A success rates. Hum Reprod 2020; 35:490.</a></li><li><a class="nounderline abstract_t">Cheng X, Zhang Y, Deng H, et al. Preimplantation Genetic Testing for Aneuploidy With Comprehensive Chromosome Screening in Patients Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. Obstet Gynecol 2022; 140:769.</a></li><li><a class="nounderline abstract_t">Kaser DJ, Racowsky C. Clinical outcomes following selection of human preimplantation embryos with time-lapse monitoring: a systematic review. Hum Reprod Update 2014; 20:617.</a></li><li><a class="nounderline abstract_t">Polanski LT, Coelho Neto MA, Nastri CO, et al. Time-lapse embryo imaging for improving reproductive outcomes: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2014; 44:394.</a></li><li><a class="nounderline abstract_t">Armstrong S, Bhide P, Jordan V, et al. Time-lapse systems for embryo incubation and assessment in assisted reproduction. Cochrane Database Syst Rev 2019; 5:CD011320.</a></li><li><a class="nounderline abstract_t">Siristatidis CS, Sertedaki E, Vaidakis D. Metabolomics for improving pregnancy outcomes in women undergoing assisted reproductive technologies. Cochrane Database Syst Rev 2017; 5:CD011872.</a></li><li><a class="nounderline abstract_t">Rubio C, Navarro-Sánchez L, García-Pascual CM, et al. Multicenter prospective study of concordance between embryonic cell-free DNA and trophectoderm biopsies from 1301 human blastocysts. Am J Obstet Gynecol 2020; 223:751.e1.</a></li><li><a class="nounderline abstract_t">Hanson BM, Tao X, Hong KH, et al. Noninvasive preimplantation genetic testing for aneuploidy exhibits high rates of deoxyribonucleic acid amplification failure and poor correlation with results obtained using trophectoderm biopsy. Fertil Steril 2021; 115:1461.</a></li><li><a class="nounderline abstract_t">Vera-Rodriguez M, Diez-Juan A, Jimenez-Almazan J, et al. Origin and composition of cell-free DNA in spent medium from human embryo culture during preimplantation development. Hum Reprod 2018; 33:745.</a></li><li><a class="nounderline abstract_t">ESHRE Guideline Group on Good Practice in IVF Labs, De los Santos MJ, Apter S, et al. Revised guidelines for good practice in IVF laboratories (2015). Hum Reprod 2016; 31:685.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="1f5e4c4d525f7e6c6d7231706d78">[email protected]</span>, Practice Committee of the American Society for Reproductive Medicine. Performing the embryo transfer: a guideline. Fertil Steril 2017; 107:882.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="763725243b361705041b58190411">[email protected]</span>, Penzias A, Bendikson K, et al. ASRM standard embryo transfer protocol template: a committee opinion. Fertil Steril 2017; 107:897.</a></li><li><a class="nounderline abstract_t">Zaat T, de Bruin JP, Goddijn M, et al. Home-based monitoring of ovulation to time frozen embryo transfers in the Netherlands (Antarctica-2): an open-label, nationwide, randomised, non-inferiority trial. Lancet 2023; 402:1347.</a></li><li><a class="nounderline abstract_t">Glujovsky D, Pesce R, Fiszbajn G, et al. Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes. Cochrane Database Syst Rev 2010; :CD006359.</a></li><li><a class="nounderline abstract_t">van Hoogenhuijze NE, Kasius JC, Broekmans FJM, et al. Endometrial scratching prior to IVF; does it help and for whom? A systematic review and meta-analysis. Hum Reprod Open 2019; 2019:hoy025.</a></li><li><a class="nounderline abstract_t">van Hoogenhuijze NE, Mol F, Laven JSE, et al. Endometrial scratching in women with one failed IVF/ICSI cycle-outcomes of a randomised controlled trial (SCRaTCH). Hum Reprod 2021; 36:87.</a></li><li><a class="nounderline abstract_t">Doyle N, Combs JC, Jahandideh S, et al. Live birth after transfer of a single euploid vitrified-warmed blastocyst according to standard timing vs. timing as recommended by endometrial receptivity analysis. Fertil Steril 2022; 118:314.</a></li><li><a class="nounderline abstract_t">Bassil R, Casper R, Samara N, et al. Does the endometrial receptivity array really provide personalized embryo transfer? J Assist Reprod Genet 2018; 35:1301.</a></li><li><a class="nounderline abstract_t">Bergin K, Eliner Y, Duvall DW Jr, et al. The use of propensity score matching to assess the benefit of the endometrial receptivity analysis in frozen embryo transfers. Fertil Steril 2021; 116:396.</a></li><li><a class="nounderline abstract_t">Doyle N, Jahandideh S, Hill MJ, et al. Effect of Timing by Endometrial Receptivity Testing vs Standard Timing of Frozen Embryo Transfer on Live Birth in Patients Undergoing In Vitro Fertilization: A Randomized Clinical Trial. JAMA 2022; 328:2117.</a></li><li><a class="nounderline abstract_t">Cozzolino M, Diáz-Gimeno P, Pellicer A, Garrido N. Use of the endometrial receptivity array to guide personalized embryo transfer after a failed transfer attempt was associated with a lower cumulative and per transfer live birth rate during donor and autologous cycles. Fertil Steril 2022; 118:724.</a></li><li><a class="nounderline abstract_t">Brown J, Daya S, Matson P. Day three versus day two embryo transfer following in vitro fertilization or intracytoplasmic sperm injection. Cochrane Database Syst Rev 2016; 12:CD004378.</a></li><li><a class="nounderline abstract_t">Glujovsky D, Farquhar C, Quinteiro Retamar AM, et al. Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology. Cochrane Database Syst Rev 2016; :CD002118.</a></li><li><a class="nounderline abstract_t">Ginström Ernstad E, Bergh C, Khatibi A, et al. Neonatal and maternal outcome after blastocyst transfer: a population-based registry study. Am J Obstet Gynecol 2016; 214:378.e1.</a></li><li><a class="nounderline abstract_t">Maheshwari A, Kalampokas T, Davidson J, Bhattacharya S. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of blastocyst-stage versus cleavage-stage embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril 2013; 100:1615.</a></li><li><a class="nounderline abstract_t">Dar S, Lazer T, Shah PS, Librach CL. Neonatal outcomes among singleton births after blastocyst versus cleavage stage embryo transfer: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:439.</a></li><li><a class="nounderline abstract_t">Song B, Wei ZL, Xu XF, et al. Prevalence and risk factors of monochorionic diamniotic twinning after assisted reproduction: A six-year experience base on a large cohort of pregnancies. PLoS One 2017; 12:e0186813.</a></li><li><a class="nounderline abstract_t">Abou-Setta AM, Al-Inany HG, Mansour RT, et al. Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis. Hum Reprod 2005; 20:3114.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine and the Practice Committee for the Society for Assisted Reproductive Technologies. Electronic address: <span class="__cf_email__" data-cfemail="1c5d4f4e515c7d6f6e7132736e7b">[email protected]</span>. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril 2021; 116:651.</a></li><li><a class="nounderline abstract_t">Combelles CM, Orasanu B, Ginsburg ES, Racowsky C. Optimum number of embryos to transfer in women more than 40 years of age undergoing treatment with assisted reproductive technologies. Fertil Steril 2005; 84:1637.</a></li><li><a class="nounderline abstract_t">Stern JE, Goldman MB, Hatasaka H, et al. Optimizing the number of cleavage stage embryos to transfer on day 3 in women 38 years of age and older: a Society for Assisted Reproductive Technology database study. Fertil Steril 2009; 91:767.</a></li><li><a class="nounderline abstract_t">Gerber RS, Kappy M, Gingold J, et al. Obstetric and Neonatal Outcomes After Transferring More Than One Embryo in Patients With Preimplantation Genetic Testing. Obstet Gynecol 2024; 143:92.</a></li><li><a class="nounderline abstract_t">Nastri CO, Lensen SF, Gibreel A, et al. Endometrial injury in women undergoing assisted reproductive techniques. Cochrane Database Syst Rev 2015; :CD009517.</a></li><li><a class="nounderline abstract_t">Lensen S, Osavlyuk D, Armstrong S, et al. A Randomized Trial of Endometrial Scratching before In Vitro Fertilization. N Engl J Med 2019; 380:325.</a></li><li><a class="nounderline abstract_t">Heneghan C, Spencer EA, Bobrovitz N, et al. Lack of evidence for interventions offered in UK fertility centres. BMJ 2016; 355:i6295.</a></li><li><a class="nounderline abstract_t">Buckett WM. A review and meta-analysis of prospective trials comparing different catheters used for embryo transfer. Fertil Steril 2006; 85:728.</a></li><li><a class="nounderline abstract_t">Derks RS, Farquhar C, Mol BW, et al. Techniques for preparation prior to embryo transfer. Cochrane Database Syst Rev 2009; :CD007682.</a></li><li><a class="nounderline abstract_t">Mains L, Van Voorhis BJ. Optimizing the technique of embryo transfer. Fertil Steril 2010; 94:785.</a></li><li><a class="nounderline abstract_t">Brown J, Buckingham K, Abou-Setta AM, Buckett W. Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women. Cochrane Database Syst Rev 2010; :CD006107.</a></li><li><a class="nounderline abstract_t">Karavani G, Ben-Meir A, Shufaro Y, et al. Transvaginal ultrasound to guide embryo transfer: a randomized controlled trial. Fertil Steril 2017; 107:1159.</a></li><li><a class="nounderline abstract_t">Abou-Setta AM, Peters LR, D'Angelo A, et al. Post-embryo transfer interventions for assisted reproduction technology cycles. Cochrane Database Syst Rev 2014; :CD006567.</a></li><li><a class="nounderline abstract_t">Pados G, Devroey P. Luteal phase support. Assist Reprod Rev 1992; 2:148.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril 2008; 89:789.</a></li><li><a class="nounderline abstract_t">Hubayter ZR, Muasher SJ. Luteal supplementation in in vitro fertilization: more questions than answers. Fertil Steril 2008; 89:749.</a></li><li><a class="nounderline abstract_t">Connell MT, Szatkowski JM, Terry N, et al. Timing luteal support in assisted reproductive technology: a systematic review. Fertil Steril 2015; 103:939.</a></li><li><a class="nounderline abstract_t">Aboulghar MA, Amin YM, Al-Inany HG, et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Hum Reprod 2008; 23:857.</a></li><li><a class="nounderline abstract_t">Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002; 17:357.</a></li><li><a class="nounderline abstract_t">Kyrou D, Fatemi HM, Zepiridis L, et al. Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Hum Reprod 2011; 26:1020.</a></li><li><a class="nounderline abstract_t">Prietl G, Diedrich K, van der Ven HH, et al. The effect of 17 alpha-hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial. Hum Reprod 1992; 7 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Kohls G, Ruiz F, Martínez M, et al. Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertil Steril 2012; 98:858.</a></li><li><a class="nounderline abstract_t">Devine K, Richter KS, Jahandideh S, et al. Intramuscular progesterone optimizes live birth from programmed frozen embryo transfer: a randomized clinical trial. Fertil Steril 2021; 116:633.</a></li><li><a class="nounderline abstract_t">Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil Steril 2009; 92:163.</a></li><li><a class="nounderline abstract_t">Polyzos NP, Messini CI, Papanikolaou EG, et al. Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis. Fertil Steril 2010; 94:2083.</a></li><li><a class="nounderline abstract_t">Bergh C, Lindenberg S, Nordic Crinone Study Group. A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Hum Reprod 2012; 27:3467.</a></li><li><a class="nounderline abstract_t">Stadtmauer L, Silverberg KM, Ginsburg ES, et al. Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertil Steril 2013; 99:1543.</a></li><li><a class="nounderline abstract_t">Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2004; :CD004830.</a></li><li><a class="nounderline abstract_t">van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011; :CD009154.</a></li><li><a class="nounderline abstract_t">Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril 2008; 90:2116.</a></li><li><a class="nounderline abstract_t">Jee BC, Suh CS, Kim SH, et al. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril 2010; 93:428.</a></li><li><a class="nounderline abstract_t">Stern JE, Lieberman ES, Macaluso M, Racowsky C. Is cryopreservation of embryos a legitimate surrogate marker of embryo quality in studies of assisted reproductive technology conducted using national databases? Fertil Steril 2012; 97:890.</a></li><li><a class="nounderline abstract_t">Wennerholm UB, Söderström-Anttila V, Bergh C, et al. Children born after cryopreservation of embryos or oocytes: a systematic review of outcome data. Hum Reprod 2009; 24:2158.</a></li><li><a class="nounderline abstract_t">Shi W, Xue X, Zhang S, et al. Perinatal and neonatal outcomes of 494 babies delivered from 972 vitrified embryo transfers. Fertil Steril 2012; 97:1338.</a></li><li><a class="nounderline abstract_t">Maheshwari A, Pandey S, Shetty A, et al. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril 2012; 98:368.</a></li><li><a class="nounderline abstract_t">Maheshwari A, Raja EA, Bhattacharya S. Obstetric and perinatal outcomes after either fresh or thawed frozen embryo transfer: an analysis of 112,432 singleton pregnancies recorded in the Human Fertilisation and Embryology Authority anonymized dataset. Fertil Steril 2016; 106:1703.</a></li><li><a class="nounderline abstract_t">Levi Dunietz G, Holzman C, Zhang Y, et al. Assisted Reproductive Technology and Newborn Size in Singletons Resulting from Fresh and Cryopreserved Embryos Transfer. PLoS One 2017; 12:e0169869.</a></li><li><a class="nounderline abstract_t">Stormlund S, Sopa N, Zedeler A, et al. Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial. BMJ 2020; 370:m2519.</a></li><li><a class="nounderline abstract_t">Wong KM, van Wely M, Mol F, et al. Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database Syst Rev 2017; 3:CD011184.</a></li><li><a class="nounderline abstract_t">Shi Y, Sun Y, Hao C, et al. Transfer of Fresh versus Frozen Embryos in Ovulatory Women. N Engl J Med 2018; 378:126.</a></li><li><a class="nounderline abstract_t">Vuong LN, Dang VQ, Ho TM, et al. IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries. N Engl J Med 2018; 378:137.</a></li><li><a class="nounderline abstract_t">Wei D, Liu JY, Sun Y, et al. Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial. Lancet 2019; 393:1310.</a></li><li><a class="nounderline abstract_t">Ishihara O, Kuwahara A, Saitoh H. Frozen-thawed blastocyst transfer reduces ectopic pregnancy risk: an analysis of single embryo transfer cycles in Japan. Fertil Steril 2011; 95:1966.</a></li><li><a class="nounderline abstract_t">Shapiro BS, Daneshmand ST, De Leon L, et al. Frozen-thawed embryo transfer is associated with a significantly reduced incidence of ectopic pregnancy. Fertil Steril 2012; 98:1490.</a></li><li><a class="nounderline abstract_t">Londra L, Moreau C, Strobino D, et al. Ectopic pregnancy after in vitro fertilization: differences between fresh and frozen-thawed cycles. Fertil Steril 2015; 104:110.</a></li><li><a class="nounderline abstract_t">Chen ZJ, Shi Y, Sun Y, et al. Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. N Engl J Med 2016; 375:523.</a></li><li><a class="nounderline abstract_t">Li J, Yin M, Wang B, et al. The effect of storage time after vitrification on pregnancy and neonatal outcomes among 24 698 patients following the first embryo transfer cycles. Hum Reprod 2020; 35:1675.</a></li><li><a class="nounderline abstract_t">Korkmaz C, Gül Yıldız Ü, Fidan U, et al. Investigation of transfer results of human embryos that were vitrified and thawed at the cleavage, morula and blastocyst stages. Zygote 2020; 28:191.</a></li><li><a class="nounderline abstract_t">De Croo I, Colman R, De Sutter P, Tilleman K. Blastocyst transfer for all? Higher cumulative live birth chance in a blastocyst-stage transfer policy compared to a cleavage-stage transfer policy. Facts Views Vis Obgyn 2019; 11:169.</a></li><li><a class="nounderline abstract_t">Riggs R, Mayer J, Dowling-Lacey D, et al. Does storage time influence postthaw survival and pregnancy outcome? An analysis of 11,768 cryopreserved human embryos. Fertil Steril 2010; 93:109.</a></li><li><a class="nounderline abstract_t">Practice Committee of American Society for Reproductive Medicine, Practice Committee of Society for Assisted Reproductive Technology. Recommendations for gamete and embryo donation: a committee opinion. Fertil Steril 2013; 99:47.</a></li><li><a class="nounderline abstract_t">Ethics Committee of the American Society for Reproductive Medicine. Disposition of abandoned embryos: a committee opinion. Fertil Steril 2013; 99:1848.</a></li><li><a class="nounderline abstract_t">Ethics Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="ca8b9998878aabb9b8a7e4a5b8ad">[email protected]</span>, Ethics Committee of the American Society for Reproductive Medicine. Defining embryo donation: an Ethics Committee opinion. Fertil Steril 2016; 106:56.</a></li><li><a class="nounderline abstract_t">Ranoux C, Foulot H, Dubuisson JB, et al. Returning to spontaneous cycles in in vitro fertilization. J In Vitro Fert Embryo Transf 1988; 5:304.</a></li><li><a class="nounderline abstract_t">Paulson RJ, Sauer MV, Francis MM, et al. In vitro fertilization in unstimulated cycles: a clinical trial using hCG for timing of follicle aspiration. Obstet Gynecol 1990; 76:788.</a></li><li><a class="nounderline abstract_t">Bodri D, Kawachiya S, Kondo M, et al. Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment. Fertil Steril 2014; 101:1001.</a></li><li><a class="nounderline abstract_t">Gordon JD, DiMattina M, Reh A, et al. Utilization and success rates of unstimulated in vitro fertilization in the United States: an analysis of the Society for Assisted Reproductive Technology database. Fertil Steril 2013; 100:392.</a></li><li><a class="nounderline abstract_t">Shaulov T, Vélez MP, Buzaglo K, et al. Outcomes of 1503 cycles of modified natural cycle in vitro fertilization: a single-institution experience. J Assist Reprod Genet 2015; 32:1043.</a></li><li><a class="nounderline abstract_t">Kamath MS, Kirubakaran R, Mascarenhas M, Sunkara SK. Perinatal outcomes after stimulated versus natural cycle IVF: a systematic review and meta-analysis. Reprod Biomed Online 2018; 36:94.</a></li><li><a class="nounderline abstract_t">Haemmerli Keller K, Alder G, Loewer L, et al. Treatment-related psychological stress in different in vitro fertilization therapies with and without gonadotropin stimulation. Acta Obstet Gynecol Scand 2018; 97:269.</a></li><li><a class="nounderline abstract_t">von Wolff M. The role of Natural Cycle IVF in assisted reproduction. Best Pract Res Clin Endocrinol Metab 2019; 33:35.</a></li><li><a class="nounderline abstract_t">Allersma T, Farquhar C, Cantineau AE. Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database Syst Rev 2013; :CD010550.</a></li><li><a class="nounderline abstract_t">Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. Electronic address: <span class="__cf_email__" data-cfemail="d7bdb0b8bbb3a4a3b2beb997b6a4a5baf9b8a5b0">[email protected]</span>. In vitro maturation: a committee opinion. Fertil Steril 2021; 115:298.</a></li><li><a class="nounderline abstract_t">Balakier H, Sojecki A, Motamedi G, Librach C. Time-dependent capability of human oocytes for activation and pronuclear formation during metaphase II arrest. Hum Reprod 2004; 19:982.</a></li><li><a class="nounderline abstract_t">De Vos A, Van de Velde H, Joris H, Van Steirteghem A. In-vitro matured metaphase-I oocytes have a lower fertilization rate but similar embryo quality as mature metaphase-II oocytes after intracytoplasmic sperm injection. Hum Reprod 1999; 14:1859.</a></li><li><a class="nounderline abstract_t">Strassburger D, Friedler S, Raziel A, et al. The outcome of ICSI of immature MI oocytes and rescued in vitro matured MII oocytes. Hum Reprod 2004; 19:1587.</a></li><li><a class="nounderline abstract_t">Shu Y, Gebhardt J, Watt J, et al. Fertilization, embryo development, and clinical outcome of immature oocytes from stimulated intracytoplasmic sperm injection cycles. Fertil Steril 2007; 87:1022.</a></li><li><a class="nounderline abstract_t">Wang Z, Meng Y, Shang X, et al. Interpregnancy Interval After Clinical Pregnancy Loss and Outcomes of the Next Frozen Embryo Transfer. JAMA Netw Open 2023; 6:e2340709.</a></li><li><a class="nounderline abstract_t">Quinn MM, Rosen MP, Allen IE, et al. Interpregnancy interval and singleton pregnancy outcomes after frozen embryo transfer. Fertil Steril 2019; 111:1145.</a></li><li><a class="nounderline abstract_t">Quinn MM, Rosen MP, Huddleston HG, et al. Interpregnancy Interval and Singleton Live Birth Outcomes From In Vitro Fertilization. Obstet Gynecol 2018; 132:115.</a></li></ol></div><div id="topicVersionRevision">Topic 134342 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29117321" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Glossary on Infertility and Fertility Care, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32115183" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Definitions of infertility and recurrent pregnancy loss: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16936296" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Assessment of ovarian reserve--should we perform tests of ovarian reserve routinely?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15237009" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901282" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8641506" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15652884" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Taking a basal follicle-stimulating hormone history is essential before initiating in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7589648" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738501" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1507373" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reversing the natural decline in human fertility. An extended clinical trial of oocyte donation to women of advanced reproductive age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24532220" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16891297" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A systematic review of tests predicting ovarian reserve and IVF outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23188168" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23394782" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239869" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473395" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21954280" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25624196" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471926" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Repeated clomiphene citrate challenge testing in the prediction of outcome in IVF: a comparison with basal markers for ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533354" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521870" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705365" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650416" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyperresponders to in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071823" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387961" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Relevance of anti-Mullerian hormone measurement in a routine IVF program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18321493" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24491452" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Value of antimüllerian hormone as a prognostic indicator of in vitro fertilization outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16517563" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Value of ovarian reserve testing before IVF: a clinical decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25936238" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnostic evaluation of the infertile female: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29871795" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Appraisal of clinical complications after 23,827 oocyte retrievals in a large assisted reproductive technology program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30230393" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk of ovarian torsion is reduced in GnRH agonist triggered freeze-all cycles: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462057" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19591989" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22749225" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794678" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27047692" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antibiotic Prophylaxis for Gynecologic Procedures prior to and during the Utilization of Assisted Reproductive Technologies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315276" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259490" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevention of Venous Thromboembolism in Gynecologic Surgery: ACOG Practice Bulletin, Number 232.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35771604" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Peri-implantation glucocorticoid administration for assisted reproductive technology cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32106976" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evidence-based treatments for couples with unexplained infertility: a guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11278221" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ovulation stimulation and monitoring for in vitro fertilization</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2110078" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Embryo implantation after human in vitro fertilization: importance of endometrial receptivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2110078" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Embryo implantation after human in vitro fertilization: importance of endometrial receptivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842672" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pregnancy rates in donor oocyte cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26,457 fresh cycles from the Society for Assisted Reproductive Technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040524" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25747130" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Freeze-all policy: fresh vs. frozen-thawed embryo transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15237007" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093184" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ultrastructural characteristics of the luteal phase endometrium in patients undergoing controlled ovarian hyperstimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737072" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246470" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16935284" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cryopreserved embryo transfers suggest that endometrial receptivity may contribute to reduced success rates of later developing embryos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224151" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of day 5 or day 6 blastocysts may reflect differences in embryo-endometrium synchrony.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224151" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of day 5 or day 6 blastocysts may reflect differences in embryo-endometrium synchrony.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21505041" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22036048" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253503" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Interventions for 'poor responders' to controlled ovarian hyperstimulation (COH) in in-vitro fertilisation (IVF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18639875" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24055048" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26608695" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169382" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29935660" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparison of pregnancy rates for poor responders using IVF with mild ovarian stimulation versus conventional IVF: a guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26171903" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-acting FSH versus daily FSH for women undergoing assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440788" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607553" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056719" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813363" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738494" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Use of recombinant human chorionic gonadotropin in ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27106604" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397861" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25358904" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26149355" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31560740" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152261" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14649378" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment-associated serum FSH levels in very poor responders to ovarian stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096046" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29761478" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pain relief for women undergoing oocyte retrieval for assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29697138" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Follicular flushing during oocyte retrieval in assisted reproductive techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276564" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Complications and problems in transvaginal sector scan-guided follicle aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3350169" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pelvic infection after transvaginal ultrasound-guided ovum retrieval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1733188" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pelvic abscess complicating transcervical embryo transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419341" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Antibiotics prior to embryo transfer in ART.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633370" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Brief co-incubation of sperm and oocytes for in vitro fertilization techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1521651" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A prospective controlled evaluation of TEST-yolk buffer in the preparation of sperm for human in vitro fertilization in suspected cases of male infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29291411" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Assisted reproductive technology with donor sperm: national trends and perinatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2362007" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Fertilization failure in IVF: why and what next?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2070858" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The predictive value of idiopathic failure to fertilize on the first in vitro fertilization attempt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351601" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276436" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7890067" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Using ejaculated, fresh, and frozen-thawed epididymal and testicular spermatozoa gives rise to comparable results after intracytoplasmic sperm injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7745045" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : High fertilization and pregnancy rate after intracytoplasmic sperm injection with spermatozoa obtained from testicle biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9742624" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Optimization of culture conditions for human in vitro fertilization and embryo transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12470535" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Fundamentals of human embryonic growth in vitro and the selection of high-quality embryos for transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10783352" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Transfer of zona-free embryos improves outcome in poor prognosis patients: a prospective randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24951365" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Role of assisted hatching in in vitro fertilization: a guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25044084" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Assisted hatching: trends and pregnancy outcomes, United States, 2000-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33543903" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Preimplantation Genetic Testing for Aneuploidy: A Review of the Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145186" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Obstetrical and neonatal outcomes from the BEST Trial: single embryo transfer with aneuploidy screening improves outcomes after in vitro fertilization without compromising delivery rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29566854" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34818479" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Live Birth with or without Preimplantation Genetic Testing for Aneuploidy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32100030" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hidden in plain sight: the overstated benefits and underestimated losses of potential implantations associated with advertised PGT-A success rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36201787" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Preimplantation Genetic Testing for Aneuploidy With Comprehensive Chromosome Screening in Patients Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890606" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Clinical outcomes following selection of human preimplantation embryos with time-lapse monitoring: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890582" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Time-lapse embryo imaging for improving reproductive outcomes: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31140578" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Time-lapse systems for embryo incubation and assessment in assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28534597" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Metabolomics for improving pregnancy outcomes in women undergoing assisted reproductive technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32470458" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Multicenter prospective study of concordance between embryonic cell-free DNA and trophectoderm biopsies from 1301 human blastocysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33745720" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Noninvasive preimplantation genetic testing for aneuploidy exhibits high rates of deoxyribonucleic acid amplification failure and poor correlation with results obtained using trophectoderm biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29471395" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Origin and composition of cell-free DNA in spent medium from human embryo culture during preimplantation development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908842" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Revised guidelines for good practice in IVF laboratories (2015).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28366416" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Performing the embryo transfer: a guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292611" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : ASRM standard embryo transfer protocol template: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37678290" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Home-based monitoring of ovulation to time frozen embryo transfers in the Netherlands (Antarctica-2): an open-label, nationwide, randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091592" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30895265" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Endometrial scratching prior to IVF; does it help and for whom? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33289528" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Endometrial scratching in women with one failed IVF/ICSI cycle-outcomes of a randomised controlled trial (SCRaTCH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35710597" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Live birth after transfer of a single euploid vitrified-warmed blastocyst according to standard timing vs. timing as recommended by endometrial receptivity analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29737471" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Does the endometrial receptivity array really provide personalized embryo transfer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33926718" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The use of propensity score matching to assess the benefit of the endometrial receptivity analysis in frozen embryo transfers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36472596" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Effect of Timing by Endometrial Receptivity Testing vs Standard Timing of Frozen Embryo Transfer on Live Birth in Patients Undergoing In Vitro Fertilization: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36070983" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Use of the endometrial receptivity array to guide personalized embryo transfer after a failed transfer attempt was associated with a lower cumulative and per transfer live birth rate during donor and autologous cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27976360" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Day three versus day two embryo transfer following in vitro fertilization or intracytoplasmic sperm injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27357126" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26928152" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Neonatal and maternal outcome after blastocyst transfer: a population-based registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24083875" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of blastocyst-stage versus cleavage-stage embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480786" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Neonatal outcomes among singleton births after blastocyst versus cleavage stage embryo transfer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29107981" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Prevalence and risk factors of monochorionic diamniotic twinning after assisted reproduction: A six-year experience base on a large cohort of pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16040620" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34330423" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Guidance on the limits to the number of embryos to transfer: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16359957" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Optimum number of embryos to transfer in women more than 40 years of age undergoing treatment with assisted reproductive technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18321489" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Optimizing the number of cleavage stage embryos to transfer on day 3 in women 38 years of age and older: a Society for Assisted Reproductive Technology database study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37944144" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Obstetric and Neonatal Outcomes After Transferring More Than One Embryo in Patients With Preimplantation Genetic Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25803542" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Endometrial injury in women undergoing assisted reproductive techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30673547" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : A Randomized Trial of Endometrial Scratching before In Vitro Fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27890864" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Lack of evidence for interventions offered in UK fertility centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16500345" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A review and meta-analysis of prospective trials comparing different catheters used for embryo transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821435" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Techniques for preparation prior to embryo transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20409543" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Optimizing the technique of embryo transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091584" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28347493" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Transvaginal ultrasound to guide embryo transfer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157849" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Post-embryo transfer interventions for assisted reproduction technology cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Luteal phase support</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18406835" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18406833" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Luteal supplementation in in vitro fertilization: more questions than answers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638420" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Timing luteal support in assisted reproductive technology: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18270182" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821278" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296803" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1332985" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The effect of 17 alpha-hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22749223" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33992421" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Intramuscular progesterone optimizes live birth from programmed frozen embryo transfer: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19362303" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171629" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23019296" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465817" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266541" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Luteal phase support in assisted reproduction cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975790" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Luteal phase support for assisted reproduction cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178194" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19342034" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22265032" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Is cryopreservation of embryos a legitimate surrogate marker of embryo quality in studies of assisted reproductive technology conducted using national databases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458318" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Children born after cryopreservation of embryos or oocytes: a systematic review of outcome data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464083" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Perinatal and neonatal outcomes of 494 babies delivered from 972 vitrified embryo transfers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22698643" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27678031" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Obstetric and perinatal outcomes after either fresh or thawed frozen embryo transfer: an analysis of 112,432 singleton pregnancies recorded in the Human Fertilisation and Embryology Authority anonymized dataset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28114395" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Assisted Reproductive Technology and Newborn Size in Singletons Resulting from Fresh and Cryopreserved Embryos Transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32759285" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28349510" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Fresh versus frozen embryo transfers in assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320646" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Transfer of Fresh versus Frozen Embryos in Ovulatory Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320655" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30827784" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21377154" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Frozen-thawed blastocyst transfer reduces ectopic pregnancy risk: an analysis of single embryo transfer cycles in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22925683" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Frozen-thawed embryo transfer is associated with a significantly reduced incidence of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25956363" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Ectopic pregnancy after in vitro fertilization: differences between fresh and frozen-thawed cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27509101" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32575120" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : The effect of storage time after vitrification on pregnancy and neonatal outcomes among 24 698 patients following the first embryo transfer cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32192547" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Investigation of transfer results of human embryos that were vitrified and thawed at the cleavage, morula and blastocyst stages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31824637" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Blastocyst transfer for all? Higher cumulative live birth chance in a blastocyst-stage transfer policy compared to a cleavage-stage transfer policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19027110" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Does storage time influence postthaw survival and pregnancy outcome? An analysis of 11,768 cryopreserved human embryos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23095142" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Recommendations for gamete and embryo donation: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23481274" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Disposition of abandoned embryos: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001380" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Defining embryo donation: an Ethics Committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3230355" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Returning to spontaneous cycles in in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2216225" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : In vitro fertilization in unstimulated cycles: a clinical trial using hCG for timing of follicle aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24534290" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23623475" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Utilization and success rates of unstimulated in vitro fertilization in the United States: an analysis of the Society for Assisted Reproductive Technology database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26041679" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Outcomes of 1503 cycles of modified natural cycle in vitro fertilization: a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29111312" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Perinatal outcomes after stimulated versus natural cycle IVF: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29247514" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Treatment-related psychological stress in different in vitro fertilization therapies with and without gonadotropin stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30473207" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : The role of Natural Cycle IVF in assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23990351" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Natural cycle in vitro fertilisation (IVF) for subfertile couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33358333" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : In vitro maturation: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15033953" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Time-dependent capability of human oocytes for activation and pronuclear formation during metaphase II arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10402405" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : In-vitro matured metaphase-I oocytes have a lower fertilization rate but similar embryo quality as mature metaphase-II oocytes after intracytoplasmic sperm injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131077" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : The outcome of ICSI of immature MI oocytes and rescued in vitro matured MII oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261289" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Fertilization, embryo development, and clinical outcome of immature oocytes from stimulated intracytoplasmic sperm injection cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37906188" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Interpregnancy Interval After Clinical Pregnancy Loss and Outcomes of the Next Frozen Embryo Transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30955846" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Interpregnancy interval and singleton pregnancy outcomes after frozen embryo transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889753" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Interpregnancy Interval and Singleton Live Birth Outcomes From In Vitro Fertilization.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
